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Abstract 
Regulated gene expression is crucial for maintenance of cellular homeostasis and adaptation 
to new environments. Therefore, both transcription (the first process in gene expression) and 
proteolysis (the termination of a protein’s existence) are tightly regulated. There is growing evidence 
that the proteasome, which hydrolyses many proteins in several cellular pathways, regulates 
transcription. Much of the initial indication that proteasomes are important regulators of transcription 
was derived from observations that many transcription activators are unstable even during conditions 
of robust transcription. However, recent attention to the proteasomal regulation of transcription has 
focused on non-proteolytic functions of the proteasome whereas the importance of proteolysis itself is 
often dismissed. In my thesis I tested if it was even possible for a proteolytic role to exist in the 
activation of transcription. If the proteasome is necessary to directly activate transcription several 
predictions arise. Two of these predictions are (1) transcription activators should dynamically 
disassociate with their target promoters during transcription, and (2) inhibiting the proteasome 
inhibits transcription. 
To study the dynamics of activators, I focused on a known ubiquitylated activator, Gal4, in 
which a role for the proteasome but not proteolysis has been proposed. If Gal4 were to stably 
associate with its target promoter during transcription, then a role for Gal4 proteolysis as part of 
transcriptional activation could be clearly ruled out. I have improved upon an in vitro competition 
assay to study the association of Gal4 with its target promoter. This technique clearly demonstrates 
that Gal4 maintains a dynamic association with its targets even under conditions of activation, which 
is consistent with a potential important role of proteolytic regulation of the activator during 
transcription. 
Similarly, I have also developed a new strain of Saccharomyces cerevisiae that has greater 
sensitivity to proteasome inhibitors such as MG132. This new strain is the product of genetically 
inactivating two of the three proteolytic subunits of the proteasome. The remaining proteolytic center 
is preferentially targeted by proteasome inhibitors resulting in rapid and acute inhibition of yeast 
proteasomes. This yeast strain will be a valuable tool for many researchers studying ubiquitin and 
proteolysis. Using this yeast strain to study the induction of gene expression I show that 
transcriptional induction of certain genes is indeed sensitive to proteasome inhibition, including a 
gene where there was prior ambiguity regarding the effects of proteasome inhibition. Furthermore, 
this tool is able to reveal a greater number of genes with significant changes in gene expression under 
genome-wide transcriptional profiling. 
Together my data reveal that previous claims that proteolytic function of the proteasome is 
dispensable for transcriptional activation were incorrect as my data demonstrate an important role for 
proteasome-mediated proteolysis in transcription. 
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Chapter One: Introduction 
Transcription activation and proteolytic destruction are intertwined to properly regulated gene 
expression in surprising ways. Transcription activators, proteins that bind specific DNA sequences 
and are necessary to elevate the rate of transcription of specific genes above the basal level (activate 
transcription), posses a very peculiar quality —the ability of an activator to induce transcription is 
inversely correlated with its stability (Molinari et al. 1999; Salghetti et al. 2000; Thomas and Tyers 
2000; Salghetti et al. 2001). As activators become more potent they are destroyed more rapidly, and 
the evidence suggests that the activators are destroyed through a specific and highly regulated 
pathway —the ubiquitin proteasome system (UPS). One intriguing model describing the connection 
between the UPS and transcription activators is that of transcription activator licensing. In this model 
transcription activators are ubiquitylated and ultimately destroyed as part of the transcription 
processes, thereby linking activation and destruction (Lipford and Deshaies 2003; Muratani and 
Tansey 2003). 
The antimony of pairing activation and destruction along with the lack of a mechanism make 
this model controversial. More significantly for this thesis, the licensing model provides several 
predictions —two of which are rather simple yet have complicated and contradicting data. Therefore, 
I aimed to test these predictions in ways that would resolve these controversies and provide improved 
tools to study the mechanisms of activator licensing. 
Chapter two addresses one prediction of the licensing model: if an activator is ubiquitylated 
and destroyed during the process of transcription then it cannot possibly associate stably with the 
DNA that it binds. Proteolysis of activators is not the only cause for activator turnover, but if 
proteolysis of activators does occur then activator turnover is a necessary corollary. Conversely the 
absence of activator turnover is a clear argument against the licensing model. Although there is a 
growing body of literature that suggests that transcription factors a highly dynamic (Hager et al. 
2009), one study in particular presents a new method to measure activator association with DNA in 
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vivo and concludes from this approach that the model Saccharomyces cerevisiae activator Gal4 does 
indeed lock-onto DNA in an transcription specific context (Nalley et al. 2006). Such clear results are 
precisely what are needed to test this licensing model. However, several problems lurk beneath the 
finding of Gal4 stability. Therefore, the turnover of Gal4 during transcription required further 
examination, which is carried out in the second chapter of this thesis. 
A second controversial prediction arising from the activator-licensing model is that inhibition 
of proteasome-mediated proteolysis should inhibit transcriptional activation. The biggest difficulty for 
testing the effects of proteasome inhibitors on transcription is that inhibition of the proteasome in S. 
cerevisiae is rather wimpy. Therefore, before testing the effects of inhibiting the proteasome on 
transcription, I needed to develop an improved strategy to decrease the proteolytic power of the 
proteasome. This strategy of combining chemical and genetic approaches to inhibit the proteasome is 
described in the third chapter. 
Once I had an effective means to inhibit the proteasome I could turn to address the 
consequences of proteolysis with transcription. This area of study has its own controversy: two 
different groups looked at the induction of the same gene using the same methods to inhibit the 
proteasome and arrived at two opposite results (Lipford et al. 2005; Nalley et al. 2006). I believe one 
reason such conflicting data arise is that the typical approach used to proteasome-mediated 
proteolysis pushes the edge of what is sufficient to regulate transcription. Improving the inhibition of 
the proteasome will also improve the clarity in which the connection between proteolysis and 
transcription can be studied. In fourth chapter I use this approach to study the activation of three 
inducible genes: ARG1, INO1, and CHA1. 
Given the success of using this approach at studying individual, strongly induced genes I also 
investigated the global transcription effects of inhibiting the proteasome. Previous attempts to study 
the effects of proteasome inhibition have used incomplete inhibition of the proteasome (Fleming et al. 
2002; Dembla-Rajpal et al. 2004). In the fifth chapter I demonstrate that my more thorough approach 
to inhibiting the proteasome results in an increased number of genes that are affected by proteasome 
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inhibitors. The altered expression of these genes will provide a useful resource for future work into 
the role of proteasome-mediated proteolysis in transcription. 
The sixth and final chapter provides a summary of my work and a discussion on how 
proteasome mediated proteolysis regulates transcription activators. 
 
The Ubiquitin Proteasome System (UPS) 
The ubiquitin proteasome system (UPS) is an ATP-dependent system for the regulated 
destruction of misfolded, unnecessary, or even harmful proteins from within the cell (Hochstrasser 
1996; Hershko and Ciechanover 1998; Schwartz and Ciechanover 1999; Voges et al. 1999). The 
ubiquitylation process begins with the charging of a small 76 amino acid protein, ubiquitin, onto an 
E1 ubiquitin activating enzyme in one of the two main ATP dependent steps. Ubiquitin is then passed 
on to a second enzyme, the E2 ubiquitin conjugating enzyme. Then, via an E3 ubiquitin ligating 
enzyme, the ubiquitin moiety is passed onto the substrate through the C-terminal glycine of ubiquitin 
and an amino group on a lysine in the substrate (or the N-terminal amino group). Because ubiquitin 
itself has seven lysines, more ubiquitin molecules can be attached to form chains of ubiquitin on the 
substrate. It is the conventional wisdom that polyubiquitin chains of four or more ubiquitin peptides 
attached to the substrate target the protein to the proteasome for destruction. 
The proteasome is a large ~2 megadalton complex composed of one to two 19S regulatory 
subcomplexes and a 20S core (see Figure 1.1) (Groll et al. 1997; Bochtler et al. 1999; Voges et al. 
1999; Finley 2009; Forster et al. 2009; Nickell et al. 2009).The 19S regulatory particle itself can be 
separated into a lid subcomplex and a base subcomplex. The lid of the 19S proteasome is important 
for recognition and de-ubiquitylation of target substrates. The base of the 19S proteasome is 
composed of six different ATPase subunits (Rpt1-Rpt6) and two non-ATPase subunits (Rpn1-2). The 
19S is able to unwind substrates and translocate the target into the center of the 20S core (Benaroudj 
and Goldberg 2000; Benaroudj et al. 2003; Horwitz et al. 2005; Smith et al. 2005; Peth et al. 2009). 
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The 20S core is comprised of a series of concentric heteroheptameric rings ordered 7-7-7-
7 to form a cylinder. The three of the seven  subunits provide the proteasome with its proteolytic 
capability. The 1 subunit, Pre3, has caspase-like proteolytic activity, preferentially cleaving after 
acidic amino acids of the peptide substrate. The 2 subunit, Pup1, is a trypsin-like protease primarily 
promoting hydrolysis following basic amino acids. Finally, the 5 subunit, Pre2, has a chymotrypsin-
like proteolytic activity with preferential cleavage following large, hydrophobic amino acids (Arendt 
and Hochstrasser 1997; Heinemeyer et al. 1997; Arendt and Hochstrasser 1999; Groll et al. 1999; 
Jager et al. 1999). All three proteases depend on a catalytic threonine that is exposed of the N-
terminal of the processed peptide and located in the center of the cylinder. Access to the proteases is 
protected by the -rings, which form a gate to the interior of the cylinder opened in vivo by the 19S 
base (Smith et al. 2005; Smith et al. 2007; Rabl et al. 2008). 
Except for the gene encoding the 3 subunit, PRE9, all genes encoding 20S subunits and 
most 19S subunits are essential for the viability of the yeast. (The 4 subunit Pre6 replaces the absent 
3 subunit in pre9 yeast (Velichutina et al. 2004)). However, it is possible to replace the catalytic 
threonine with an alanine in any one of the proteolytic subunits. This will abolish the associated 
activity of that protease yet the yeast remains viable. In fact, double mutants without trypsin-like and 
caspase-like activity or without the chymotrypsin-like and caspase-like activity are viable 
(Heinemeyer et al. 1997; Arendt and Hochstrasser 1999). (There is no specific mention of yeast 
without chymotrypsin-like and trypsin-like subunits, which may be a nonviable combination of 
deletions). Of the three subunits, the only the loss of chymotrypsin-like activity stabilized model 
substrates such as the mating type transcription repressor 2 or ubiquitin-fused -galactosidase 
(Arendt and Hochstrasser 1997; Arendt and Hochstrasser 1999). It was also the loss of chymotrypsin-
like activity that had the most pronounced affect on yeast growth at elevated temperatures. Together 
these data have been used to argue that it is the chymotrypsin-like activity that is the primary and 
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rate-limiting protease for proteasome-mediated proteolysis (Kisselev and Goldberg 2001; Kisselev et 
al. 2006). 
The importance of the UPS in the cell is reflected in the numerous cell pathways it regulates 
such as cell cycle progression (King et al. 1996; Zachariae and Nasmyth 1999), DNA repair (Krogan 
et al. 2004; Daulny and Tansey 2009), transcription (Auld and Silver 2006), protein quality control 
(Goldberg 2003), and organelle distribution (Campbell et al. 1994). Although not all ubiquitylation 
events lead to the proteasome, proteolysis is an important mechanism preventing the toxic 
accumulation of abundant or misfolded proteins and provides an irreversible step that can provide 
directionality to any given cell process. 
 
Transcription and Transcription Activators 
The process of transcription can be thought of in three phases: initiation, elongation, and 
termination. Accompanying elongation and termination are several important RNA-processing 
events. RNA polymerase II (RNApolII) is responsible for the production mRNA and the challenges 
of regulating transcription center on correct and efficient recruitment of RNApolII and regulating its 
processivity once transcription initiation has begun. The recruitment of RNApolII itself presents 
several challenges; not only must RNApolII arrive at the correct genes, it must arrive at the correct 
start sites, at the correct time. The challenges of recruiting RNApolII are accomplished between the 
cooperation of cis DNA regulatory elements typically located 5’ (upstream) of the transcription start 
site, chromatin structure, and trans regulatory proteins (transcription factors). 
A certain set of transcription factors is typically associated with RNApolII recruitment and 
transcription of the initial few nucleotides. These general transcription factors (GTF) include TFIID, 
which is a protein complex with several proteins necessary to position RNApolII at the transcription 
start site (e.g. TATA-binding protein (TBP)), TFIIB and TFIIA which bridge the binding of DNA and 
TFIID to the association of RNApolII and TFIIIF, and TFIIE and TFIIH, which assist in the ATP-
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dependent opening of DNA to start transcription (Orphanides et al. 1996; Hampsey 1998). In addition 
to the GTFs, the mediator complex commonly works to coordinate recruitment of RNApolII with the 
activator (Holstege et al. 1998; Kornberg 2005). The mediator complex has several other functions 
beyond serving as a bridge between activator and RNApolII. Srb10/Ssn3/Cdk8 regulates the activity 
of RNA polymerase by phosphorylation of the C-terminal domain (CTD) of the Rpb1 (Kuchin et al. 
1995; Liao et al. 1995), and another subunit Nut1 has histone acetyltransferase (HAT) functions 
(Lorch et al. 2000). Thus, the mediator has been proposed to facilitate the function of activators to 
recruit RNApolII, dispatch the RNApolII into an elongation phase, and facilitate re-initiation for 
subsequent rounds of transcription (Svejstrup et al. 1997; Lewis and Reinberg 2003). 
In addition to the GTFs and mediator complex, numerous co-activators, such as SAGA, RSC, 
and SWI/SNF, facilitate RNApolII recruitment and initiation (Guarente 1996; Naar et al. 2001; 
Narlikar et al. 2002). These co-activators not only provide additional scaffolding structures to 
stabilize the association of RNApolII to the promoter, but these co-activators also alter the chromatin 
architecture, both of the promoter and the transcribed region to facilitate RNApolII binding and later 
elongation. Co-activators seem to primarily function by modifying or remodeling nucleosomes to 
make the chromatin more accessible for RNApolII to transcribe the gene while at the same time 
making the nucleosome structure unfavorable for spurious transcripts to be generated from cryptic 
promoter-like elements. 
Although all these components —GTFs, mediator, co-activators, and nucleosomes —are 
necessary to have efficient and accurate transcription, the ability to regulate the levels of transcription 
in response to changing cellular needs typically operates through transcription activators. Most 
transcription activators have two general modules:  a DNA binding domain (DBD) that recognizes 
specific DNA sequences or upstream activating sequences (UAS) in the promoter and a transcription 
activation domain (TAD) that is responsible for binding and recruiting co-activators, mediator, and 
GTFs (Ptashne 1988). For example when the yeast activator Gal4 is induced it is able to bind 
components of the co-activators SAGA and NuA4, the Mediator complex, and the GTF TFIID 
18
(Reeves and Hahn 2005). Transcription activators are (1) tightly controlled by the cell to adapt to 
changes in transcriptional demands, (2) flexible to interact with many different molecules of the pre-
initiation complex, and (3) specific to bind specific promoters to provide the cell with a regulated 
means to increase the transcription from particular sets of genes.  
There are multiple means to regulate transcription activators: controlling abundance (e.g. -
catenin) (Aberle et al. 1997; Hart et al. 1999; Lagna et al. 1999; Latres et al. 1999; Winston et al. 
1999), removal of inhibitory domains (e.g. NF--B) (Sears et al. 1998; Orian et al. 1999; Moorthy et 
al. 2006; Cohen et al. 2009; Kravtsova-Ivantsiv et al. 2009), localization within the cell (e.g. Spt23) 
(Hoppe et al. 2000; Chellappa et al. 2001; Rape et al. 2001), availability of co-activator targets (e.g. 
LIM homeodomain) (Ostendorff et al. 2002; Gungor et al. 2007), and stability with co-activators (e.g. 
Gal4) (Lee et al. 2005). Interestingly the UPS regulates each of these processes (Lipford and Deshaies 
2003; Muratani and Tansey 2003). 
 
The Transcription-Proteasome Nexus 
The proteasome has been proposed to regulate several steps throughout the process of 
transcription (see Figure 1.2) (Collins and Tansey 2006). However, not all proposed mechanisms 
involve the proteolytic ability of the proteasome. Instead much of the debate is not whether there 
exists a role for the proteasome in transcription but instead it is whether the proteasome requires its 
proteolytic functions or if it uses non-proteolytic mechanisms to regulate transcription. In addition to 
proteolysis the proteasome can de-ubiquitylate, unfold, and translocate substrates making the 
proteasome somewhat of a “reverse chaperone” (Braun et al. 1999; Navon and Goldberg 2001; Liu et 
al. 2007). 
The issue of the proteasome functioning as a non-proteolytic molecule, even to the extent that 
a subcomplex of the 19S bases functions independently of the rest of the proteasome is the product of 
a spontaneous mutational suppressor of a truncated version of Gal4 (Matsumoto et al. 1980). This 
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mutant, gal4D, missing much of its activation domain, could not induce GAL gene expression. 
However a pair of spontaneous second site mutations, sug1 and sug2, suppressed the galactose 
negative phenotype (Swaffield et al. 1992). Johnston et al building on this observation proposed that 
these proteins formed a new class of transcriptional co-activators. When these mutations were 
eventually found to be components of the 19S proteasome (rpt6 and rpt4 respectively (Rubin et al. 
1996)), the relevance of the ability Rpt6 and Rpt4 as coactivators was strongly doubted. The 
importance of the proteasome in regulating transcription has come from several fronts. First, it has 
been demonstrated that the ability of the rpt6 and rpt4 mutations to suppress specific gal4 mutations 
was not simply due to increased abundance of gal4 (Russell and Johnston 2001). Second, the 
proteasome has been detected at many genes (Auld et al. 2006; Sikder et al. 2006)—although 
conclusions regarding the widespread non-overlap of 19S and 20S subunits may be a consequence of 
using tags to detect the proteasome (F. Geng, personal communication), it seems that the proteasome 
is indeed found at genes in a transcription dependent manner. Third, there is accumulating evidence 
that transcription activators are ubiquitylated and unstable (Molinari et al. 1999; Salghetti et al. 2000; 
Salghetti et al. 2001; Lipford and Deshaies 2003; Muratani and Tansey 2003). Increasing the potency 
of activators decreases the stability of activators whereas ubiquitylation of an activator allows it to 
bypass the need for an ubiquitin ligase to induce transcription. 
The idea that the proteasome functions non-proteolytically to regulate transcription has merit. 
First, the proteasome has “reverse chaperone” capabilities of unwinding substrates (Braun et al. 1999; 
Navon and Goldberg 2001; Liu et al. 2002). Second, the 19S apart from the 20S proteolytic core, can 
increase the stability of association between SAGA, Gal4, and the GAL UAS (Lee et al. 2005). Third, 
histones, which were the first substrates known to be ubiquitylated, undergo multiple post-
translational modifications. In particular, H2B can be mono-ubiquitylated on lysine-123 (Sun and 
Allis 2002). The mono-ubiquitylation of H2B is necessary for di- and tri-methylation on H3 lysines 4 
and 79 in what has been reported to be a 19S but not 20S dependent process (Ezhkova and Tansey 
2004; Laribee et al. 2007). Finally, another ATPase complex, the Cdc48 complex, has been reported 
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to destabilize the transcription repressor 2 in an ubiquitylation-dependent process (Wilcox and 
Laney 2009). Cdc48 does not have proteolytic activities and therefore any mechanism it has on 
detecting and displacing ubiquitylated 2 is non-proteolytic, providing an example of the type of non-
proteolytic remodeling that may be possible by the proteasome. 
Given the merit of non-proteolytic mechanisms of the proteasome in regulating transcription 
it is reasonable to ask if the proteolytic ability of the proteasome is even necessary to directly regulate 
transcription beyond controlling transcription factor abundance. There are at least two reasons to 
suspect that the proteolytic role of the proteasome is important to directly regulate transcription. First, 
there is growing evidence for widespread distribution of the 20S proteolytic core on chromatin 
coupled with only shaky evidence that 19S subunits are indeed separate from the 20S subunits (Auld 
and Silver 2006; Sikder et al. 2006). Second, and carrying much more weight, is the instability of 
transcription activators (Molinari et al. 1999; Salghetti et al. 2000; Salghetti et al. 2001; Lipford and 
Deshaies 2003; Muratani and Tansey 2003). It is not just the ubiquitylation of these activators that is 
associated with transcription but their instability, which is presumably a product of proteasome-
mediated proteolysis. But this then raises the question, “In what capacity is proteasome-mediated 
proteolysis directly connected to activating transcription?” The model of activator licensing may be 
relevant.  
 
The Licensing Model of Transcription Activators 
 The model of transcription activator licensing draws upon analogy with the licensing of the 
DNA pre-replication complex (pre-RC) (Stillman 1996; Drury and Diffley 2009). In the licensing of 
the pre-RC, the origin recognition complex (ORC) has bound DNA at specific sequence elements. 
During early G1 phase of the cell cycle, Cdc6 binds to ORC and facilitates the binding of MCM 
proteins. S-Cdk later activates the pre-RC and phosphorylates Cdc6, which is then ubiquitylated and 
destroyed preventing re-initiation of DNA replication. The analogy between activator licensing and 
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replication licensing however breaks down in that it is clear that replication must fire once and only 
once per cell cycle, whereas no such pressing need is placed on transcription. 
Nevertheless, the analogy is useful in laying out the three regulatory events and connecting it 
to activation. In this case, activators facilitate the binding of co-activators, GTFs, and RNApolII. 
Within the assembled initiation complex are kinases that are not only important for phosphorylation 
of the RNApolII CTD to facilitate the transition to productive elongation, but also for the 
phosphorylation of the activator. At least two activators, Gal4 and Gcn4, are known to be 
phosphorylated by a component of the Mediator complex (Ssn3/Srb10/Cdk8) and by a component of 
the GTF, TFIIH (Hirst et al. 1999; Chi et al. 2001; Lipford et al. 2005; Muratani et al. 2005). Both 
activators are ubiquitylated in response to these phosphorylation events and both are unstable, 
particularly during active transcription. Inhibiting the ubiquitylation of Gal4 and Gcn4 has led to loss 
of transcription in the case of Gcn4 (Lipford et al. 2005) and the loss of co-transcriptional processing 
in the case of Gal4 (Muratani et al. 2005). Therefore, it is suspected that Gal4 and Gcn4 and perhaps 
other activators are phosphorylated to mark that productive transcription is underway. This leads to 
ubiquitylation and subsequently destruction by the proteasome (see Figure 1.3). 
The purpose of such a regulatory system may not be immediately obvious (molecular clocks 
(O'Malley 2009) and removal of “spent” activators (Lipford and Deshaies 2003; Lipford et al. 2005) 
have been proposed), but the model not only accounts for known data but provides clear, testable 
predictions. Specifically, because I am interested in the connection between the proteasome and 
transcription, two predictions that I have tested are (1) that transcription activators cannot stably 
associate with the target promoter if proteolysis is a necessary part in the process of licensing 
activators, and (2) that inhibiting the proteasome must have some inhibitory effect on genes whose 
transcription depends on licensed activators if proteolysis is a necessary part in the process of 
licensing activators. These predictions are interesting because not only are they clear and testable, but 
there has been controversy and contradictory data that purportedly supports or refutes each of these 
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predictions. My work then will not only test these two predictions but it will resolve the controversy 
and provide improved tools to study transcription activator and proteasome function. 
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Chapter Two: The Turnover of Gal4 on Chromatin During Activation 
Introduction 
The Gal4 activator is the central regulator of galactose metabolism in S. cerevisiae (Johnston 
and Carlson 1992). Yeast demonstrate a marked preference for glucose as their primary carbon source 
to such an extent that yeast repress the synthesis of enzymes required to metabolize other 
carbohydrates (e.g. galactose) when grown in the presence of glucose. If, however, yeast are deprived 
of glucose and are instead supplied with galactose, transcription of a small set of genes rapidly 
increases, driven by the Gal4 activator (Ren et al. 2000). In between the active transcription of the 
induced state (galactose media) and negligible transcription of the repressed state (glucose media), the 
GAL genes have basal levels of transcription in non-inducing media (e.g. raffinose or glycerol and 
lactic acid media) (Johnston and Carlson 1992). Under the repressed and non-induced states, Gal80 
inhibits the activity of Gal4. Additionally, during repression, GAL genes are tightly controlled to 
prevent extraneous expression by the repressor Mig1 and the co-repressors Cyc8-Tup1 (Lamphier and 
Ptashne 1992; Papamichos-Chronakis et al. 2004). However, upon induction with galactose, the 
inhibitory effects of Gal80 on Gal4 are relieved in a Gal3 dependent manner thereby allowing Gal4 to 
function as an activator (Bhat and Hopper 1992). (Gal1, which is paralogous to Gal3, can also 
activate Gal4 in the presence of galactose but the concentration of Gal1 is not typically sufficient to 
relieve Gal4 repression by Gal80 except in yeast that recently induced GAL gene expression (Ptashne 
2008)). 
Gal4 has three phosphoisoforms that are resolvable by SDS-PAGE western blots (Mylin et al. 
1990; Sadowski et al. 1991; Hirst et al. 1999). Under non-inducing conditions only the faster 
migrating two isoforms (a and b) can be detected. Gal4a and Gal4b are unstable; Gal4 levels 
progressively decrease when treated with cycloheximide. The instability of Gal4a and Gal4b is 
presumably regulated by the UPS because deletion GRR1, encoding an E3 ligase, stabilizes Gal4 
when treated with cycloheximide (Muratani et al. 2005). When yeast are switched to inducing 
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conditions a third, slower moving, phosphoisoform of Gal4 (c) can now be detected. Grr1 no longer 
regulates Gal4 in the presence of galactose and Gal4a and Gal4b become stable. However, the 
activation-associated phosphoisoform of Gal4, Gal4c, is unstable and ubiquitylated in an Mdm30-
dependent process (Muratani et al. 2005). 
Several pieces of evidence provide a compelling case that the ubiquitylation and presumably 
destruction of Gal4 occurs at its target promoters. First, the unstable portion of Gal4, Gal4c, is only 
detected during conditions that also induce Gal4-dependent transcription (Mylin et al. 1990; 
Sadowski et al. 1991; Hirst et al. 1999). Second, the kinases that are responsible for Gal4c formation 
have been identified as components of the GTF TFIIH and of the Mediator complex (Hirst et al. 
1999). Gal4 is known to interact with the Mediator complex and another GTF, TFIID, at the promoter 
(Reeves and Hahn 2005), making it plausible that Gal4c forms at the promoter. Third, Mdm30, the E3 
ligase that mediates Gal4 ubiquitylation in galactose and the instability of Gal4c, is detected at the 
GAL1 promoter when the yeast are grown in galactose (Muratani et al. 2005). Fourth, mdm30 yeast 
are galactose negative and fail to efficiently process GAL1 mRNA and incorporate those messages 
into polyribosome complexes for translation (Muratani et al. 2005). Finally, Gal4 is not unusual in 
this regards; several other activators are unstable in the context of transcription (McNally et al. 2000; 
Becker et al. 2002; Metivier et al. 2003; Reid et al. 2003; Stavreva et al. 2004; Bosisio et al. 2006; 
Johnson et al. 2008; Karpova et al. 2008; Hager et al. 2009). 
However, using a recently developed competition chromatin immunoprecipitiation (cChIP) 
technique, Nalley et al reported the turnover of Gal4 only occurs when yeast are in non-inducing 
conditions (Nalley et al. 2006). When transcription occurs, Gal4 is observed to lock onto its target 
promoter. Elaborating on this model, the Kodadek group proposed that Gal4 is stabilized by the 
monoubiquitylation through a yet unidentified E3 ligase from mammalian nuclear extracts (Ferdous 
et al. 2007; Archer et al. 2008a; Archer et al. 2008b; Ferdous et al. 2008; Archer and Kodadek 2010). 
In their model, Gal4 is recognized by a subcomplex of the 19S base (APIS), and dislodged from the 
promoter. Gal4 is mono-ubiquitylated under inducing conditions, which prevents the recognition of 
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Gal4 by the APIS complex and consequently Gal4 stably associates with the promoter and activates 
transcription. 
There are many significant problems with the model put forth by the Kodadek group. The 
primary evidence for the APIS complex comes from the ability to detect certain 19S but not 20S 
proteins from co-immunoprecipitation with Gal4 or to detect certain 19S but not 20S protein 
localization to the GAL1 promoter, (Gonzalez et al. 2002) resulting in an argument from silence for 
the independent existence of the APIS complex. Second, the evidence of Gal4 ubiquitylation in vivo 
supports that there is substantial polyubiquitylation rather than predominantly mono-ubiquitylation of 
Gal4 (Muratani et al. 2005). Similarly, the E3 responsible for mono-ubiquitylation of Gal4 remains to 
be identified. Mono-ubiquitylation of Gal4, then, may be an artificial phenomenon that was achieved 
through the use of mammalian cell extracts. Moreover, this model raises the issue of whether or not 
Gal4 stably locks onto its target promoter to activate transcription even though the whole cell 
population of the activation associated Gal4c isoform is unstable with cycloheximide treatment. 
The competitive ChIP technique used to measure the stability of Gal4 with its promoter is an 
in vivo competition assay between two activators that each bind a common DNA target-sequence. In 
this case the two activators are two distinct versions of Gal4, endogenous Gal4 and competitor Gal4, 
which compete for access at the GAL1 promoter. Endogenous Gal4 is genomically encoded and can 
be detected at the UASGAL by ChIP using antibodies directed against the Gal4 TAD. Therefore, 
although it is necessary that competitor Gal4 share a common DBD with endogenous Gal4, the 
competitor Gal4 competitor cannot have the same epitope as endogenous Gal4 and therefore it uses a 
different TAD, namely the VP16 TAD. Association of competitor Gal4 with the GAL1 promoter is 
measured by ChIP with antibodies against and N-terminal Myc-epitope tag. Finally, competitor Gal4 
is engineered to have an estrogen-binding domain (EBD) from the human estrogen receptor alpha. 
This EBD is sandwiched between the VP16 TAD and the Gal4 DBD and serves as the trigger sensor 
for the competition experiment. In the absence of ligand, EBD is bound by Hsp90 and sequestered in 
the cytoplasm away from the GAL1 promoter (Fankhauser et al. 1994; Picard 2000). Thus, in the 
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absence of an appropriate ligand, such as 17--estradiol, only endogenous Gal4 is present in the 
nucleus. Upon addition of an appropriate ligand, Hsp90 releases competitor Gal4, which moves to the 
nucleus and competition ensues (see Figure 2.1). If Gal4 stably binds the UASGAL then endogenous 
Gal4 levels should remain constant even after competition is triggered and competitor Gal4 should 
not be detected at the GAL1 promoter. Conversely, the loss of endogenous Gal4 and the appearance 
of competitor Gal4 is evidence of competition and activator turnover. 
The Kodadek group argued, based on this assay, that Gal4 is labile under non-inducing 
conditions but locks onto the GAL1 promoter upon induction with galactose (Nalley et al. 2006). 
However, from the data that they presented it was ambiguous whether or not competitor Gal4 was 
arriving to the GAL1 promoter, and thus it was not certain that no exchange between endogenous and 
competitor Gal4 occurred. For this reason, and because Gal4c is unstable, I re-examined the stability 
of Gal4 on the GAL1 promoter using qPCR rather than ethidium bromide stained gels to quantify the 
stability of the Gal4 association with its target promoter. 
 
Experimental Procedures 
Yeast strains 
I list the strains used in the course of this study in table 2.1. The pTK0601 plasmid (Nalley et 
al. 2006), bearing the competitive Gal4 (cGal4), was transformed using the high efficiency 
transformation using lithium acetate and PEG, as described by Gietz and Woods (Gietz and Woods 
2002). I deleted PDR5 in the designated strains using gene replacement with LEU2 by homologous 
recombination. I synthesized the knockout cassette by PCR using pRS405 as a template, and 
transformed the cassette again using the lithium acetate and PEG transformation method (Gietz and 
Woods 2002). 
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Table 2.1: Yeast Strains Used in This Chapter 
Strain Genotype Source 
BY4741 Mata his31 leu20 met150 ura30 Open Biosystems 
BY4741 gal4 Mata his31 leu20 met150 ura30 gal4::KanMX6 Open Biosystems 
GAC101 Mata his31 leu20 met150 ura30 + pTK0601 (cGAL4, 
HIS3) 
This study 
GAC102 Mata his31 leu20 met150 ura30 gal4KanMX6 + 
pTK0601 (cGAL4, HIS3) 
This study 
BY4742 Mat his31 leu20 lys20 ura30 Open Biosystems 
BY4742 gal4 Mat his31 leu20 lys20 ura30 gal4::KanMX6 Open Biosystems 
BY4742 
pdr5 
Mat his31 leu20 lys20 ura30 pdr5::LEU2 This study 
BY4742 gal4 
pdr5 
Mat his31 leu20 lys20 ura30 gal4::KanMX6 
pdr5::LEU2 
This study 
GAC111 Mat his31 leu20 lys20 ura30 pdr5::LEU2 + 
pTK0601 (cGAL4, HIS3) 
This study 
GAC112 Mat his31 leu20 lys20 ura30 gal4::KanMX6 
pdr5::LEU2 + pTK0601 (cGAL4, HIS3) 
This study 
 
 
Table 2.2: Plasmids Used in This Chapter 
Plasmid Features Source 
pTK0601 Myc - Gal4 DBD - ER EBD -VP16 TAD (HIS3) (Nalley et al. 
2006) 
pRS405 Yeast integrative vector with LEU2 marker (Sikorski and 
Hieter 1989) 
 
Cycloheximide Treatment 
I treated BY4742 yeast grown in CSM 2% galactose with 10 g /ml cycloheximide (Sigma) 
from a 1000x stock solution in ethanol. I collected samples 15, 30, and 60 minutes after the start of 
the cycloheximide treatment or ethanol in addition to an untreated control (t0). I reserved 2ml of each 
sample to monitor the efficacy of cycloheximide treatment by following the growth of the culture as 
determined by change in A600. The remaining culture was used for chromatin immunoprecipitation 
(ChIP) as described below. 
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Gal4 Competition 
Please refer to figure 2.1 for a diagram of the competitive ChIP procedure. For the 
competitive ChIPs done in non-inducing conditions, yeast were grown in CSM 2% glycerol 2% lactic 
acid. For the competitive ChIPs in inducing conditions, I induced GAL gene transcription by 
transferring yeast grown in CSM 2% raffinose to CSM 2% galactose. After one hour in galactose, I 
started the competition assay with 1 M 17--estradiol (Sigma) in DMSO or 100 M 4-hydroxy 
tamoxifen (4-OHT) (Sigma) in ethanol. I collected samples 15, 30, and 60 minutes after the start of 
competition in addition to an untreated control (t0) to be processed by ChIP as described below. 
 
Chromatin Immunoprecipitation 
I used a ChIP procedure described by Muratani et al (Muratani et al. 2005). To 230 ml of 
yeast culture, I added 6.4 ml of 37% formaldehyde solution (Fisher) and cross-linked for 20 minutes 
at room temperature. I stopped the cross-linking reaction by the addition of 14.5 ml of 2 M glycine 
for 5 minutes. I then collected the yeast cells by gentle centrifugation (5 minutes at 4000 rpm) and 
washed the cell pellet twice with ice cold 1x TBS. The washed cell pellet was then flash frozen in 
liquid nitrogen. I lysed the yeast in ChIP lysis buffer (50 mM HEPES/KOH (pH 7.5), 150 mM NaCl, 
1 mM EDTA, 0.5% Triton X-100, 0.1% DOC, 0.1% SDS, 5 mM NaF) by bead beating. Cell lysates 
were sonicated to approximately 500 base pairs fragments. I incubated the sheared chromatin solution 
with protein A / protein G agarose beads (Roche) for 1 hour at 4°C. Then I collected the cleared 
chromatin solution to be incubated with the appropriate antibody. Endogenous Gal4 was monitored 
using C-10 anti-Gal4 anitbody (Santa Cruz), whereas the competitive Gal4 was followed using the 
Myc-epitope tag and the AB1 anti-Myc antibody (Calbiochem). Following overnight incubation with 
the antibodies, I added protein A / protein G agarose beads for an hour at 4°C, after which I washed 
the beads twice with ChIP lysis buffer, once with DOC wash buffer (10 mM Tris-Cl (pH 8.0), 0.25 M 
LiCl, 0.5% NP-40 alternative, 0.5% DOC, 1 mM EDTA), and twice with 25x Tris-EDTA buffer. I 
eluted the pulldown chromatin using TES buffer (50 mM Tris-Cl (pH 8.0), 10 mM EDTA, 1% SDS) 
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incubated at 65°C for 20 minutes. I reversed the cross-linking of the enriched chromatin by 
incubating overnight at 65°C. Proteins were digested using 2g proteinase K (Roche) at 42°C for two 
hours, followed with a phenol:chloroform extraction and ethanol precipitation of the DNA. 
I quantified the amount of DNA that came down in the immunoprecipitation by qPCR with 
SYBR green PCR mix (Applied Biosystems). Calculating enrichment was done as described by 
Ezhkova et al. The automatically-derived cycle thresholds were obtained from triplicate samples of 
the immunoprecipitated DNA for both the amplicon of interest (CIPA) and a reference locus (CIPR) as 
well as corresponding threshold values from chromatin reserved from prior to the 
immunoprecipitation steps (CINA and CINR) respectively. Fold enrichment was then calculated as [2(IPR-
IPA)] ÷ [2(INR-INA)]. I used the ACT1 ORF (ACT1-Q1 ACT1-Q2 oligonucleotides) as my reference locus 
to normalize for Gal4 signal binding to the GAL1 promoter (GAL1-Q1 and GAL1-Q2 
oligonucleotides). ChIP signals are expressed as percent of the untreated (t0) control except for Figure 
2.7, which expresses the ratio of treated (or competition present) versus mock treated (or no 
competition present), and for Figure 2.8, which is expressed as percent of a competitor Gal4 bound 
after one hour of treatment with 100 M hydroxy tamoxifen in a gal4 (no endogenous Gal4) strain.   
 
Results 
Cycloheximide treatment leads to a decrease in Gal4 at the promoter 
One approach to monitor the stability of proteins is to shutdown translation with 
cycloheximide. Muratani et al used this technique to demonstrate that Gal4 is unstable, particularly 
the phosphoisoform associated with transcriptional activity (Muratani et al. 2005). The success of this 
approach to study the stability of Gal4 in whole cell extracts, motivated me to determine if the 
stability of Gal4 on chromatin corresponded with the instability of Gal4c when treated with 
cycloheximide. I treated yeast with either cycloheximide to inhibit translation or ethanol as a control 
and measured the levels of GAL1 promoter DNA bound by Gal4 at three time points post-treatment 
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by ChIP (Figure 2.2). Whereas ethanol treatment did not significantly change the Gal4 ChIP signal at 
the GAL1 promoter, treatment with cycloheximide produced a rapid and substantial loss of Gal4 
bound to the GAL1 promoter. Within fifteen minutes, nearly half the initial Gal4 signal was lost, and 
by an hour as much as eighty percent of the initial Gal4 no longer associates with the promoter. Thus, 
the loss of Gal4 on the promoter approximates the global instability of Gal4c with cycloheximide 
treatment but not the stability of isoforms Gal4a and Gal4b (Muratani et al. 2005). Furthermore, these 
results are in stark contrast to the report that Gal4 locks onto chromatin during active transcription 
(Nalley et al. 2006). Therefore, to address the disconnect between stable Gal4 observed by Nalley et 
al and unstable Gal4 that both Muratani et al and I observed, I turned to the competitive ChIP assay. 
 
17--estradiol is not suitable for Gal4 competition assays 
 The competitive ChIP assay has the advantage over cycloheximide treatment in that —at least 
in theory —it is more direct in its ability to focus in on a single DNA binding protein (see Figure 
2.1). To demonstrate that I could obtain similar results as Nalley et al (Nalley et al. 2006) I performed 
their competitive ChIP as described using 17--estradiol to induce competition and DMSO treatment 
for the non-competition control (Figure 2.3). Under galactose inducing conditions, the Gal4 ChIP 
signal does not significantly change from the untreated (t0) control. The DMSO treated, non-
competitive controls, have a slight increase in their Gal4 ChIP signal but overall treatment with 
DMSO does is not significantly different from the untreated (t0) control or the competition samples. 
Therefore, performed this way, there does not appear to be any significant effect by competition, and 
endogenous Gal4 appears to stably associate with the GAL1 promoter consistent with observations of 
the Kodadek group (Nalley et al. 2006). 
 The induction of GAL genes in the presence of 17--estradiol is a novel approach that has not 
been fully characterized. Therefore, I repeated the competition experiments using a strain without 
competitor Gal4 rather than treating with DMSO as the non-competitive control. Consequently I 
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treated all samples with 17--estradiol (Figure 2.4). As in the previous set of experiments, the 
endogenous Gal4 ChIP signal in the presence of competitor did not significantly deviate from the 
Gal4 signal prior to competition (t0). However, when yeast without competitor Gal4 were treated with 
17--estradiol the Gal4 signal increased significantly (nearly a four-fold increase at one point) rather 
than remaining flat. This finding indicates that 17--estradiol potentially increases the Gal4 signal 
apart during competition and as such renders the competition experiment invalid. Done properly, 
competition experiments only change one variable at a time (i.e. competitor Gal4 concentration in the 
nucleus), while keeping the other conditions constant (i.e.. the amount of endogenous Gal4). 
Treatment with 17--estradiol, by increasing the Gal4 ChIP signal in the absence of competitor Gal4 
violates this basic tenant of carefully designed competition assays. 
 The odd phenomenon of increasing Gal4 ChIP signals through treatment with 17--estradiol 
is only observed in the context of inducing conditions (i.e. galactose media) but not during non-
inducing conditions (i.e. glycerol-lactic acid media) (Figure 2.5). When yeast grown in non-inducing 
conditions are treated with 17--estradiol, the Gal4 ChIP signal does not significantly change from 
initial (t0) levels of Gal4 when no competitor is present. This is the type of conditions that are 
necessary to conduct proper competition experiments, and as such it is possible to observe the rapid 
and dramatic loss of Gal4 from the GAL1 promoter. Nearly ninety percent of the signal is lost in just 
the first fifteen minutes of competition. The peculiar effect of 17--estradiol on the Gal4 ChIP signal 
with inducing media but non-inducing media explains why Nalley et al observed that Gal4 was stable 
during inducing whereas it was unstable in non-inducing media (Nalley et al. 2006). 
 
Gal4 Turnover at An Active Locus 
 The mechanism behind the increased Gal4 ChIP signal as a consequence of treatment with 
17--estradiol under activating conditions is unknown. If another molecule could bind to the 
estrogen-binding domain of competitor Gal4 to initiate competition and yet not artificially inflate 
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Gal4 ChIP signals in the absence of competitor Gal4, then the competition ChIP assay could be 
salvaged to test if Gal4 stably associates with its promoter. I hypothesized that 4-hydroxy tamoxifen 
(4-OHT) was possibly such a molecule. Yeasts do have known estrogen binding proteins: S. 
cerevisiae has two old yellow enzymes (Feldman et al. 1982; Burshell et al. 1984) that bind estrogen 
and the Candida albicans homologue of S. cerevisiae OYE2, EBP1 (for estrogen binding protein 1), is 
an important virulence factor and has been proposed to mediate the metabolic changes necessary for 
tissue invasion for yeast infections (Skowronski and Feldman 1989; Madani et al. 1994). 
Significantly, although Oye2, Oye3, and C. albicans Ebp1 have a strong affinity for 17--estradiol, 
they do not efficiently bind 4-hydroxy tamoxifen (4-OHT) (Burshell et al. 1984; Madani et al. 1994). 
Thus, 4-OHT represents a ligand for the human EBD in competitor Gal4 without any known binding 
proteins in yeast and may therefore be a more suited for a Gal4 competition ChIP assay. 
 I used 4-OHT to drive the Gal4 competition assay (Figure 2.6). Unlike 17--estradiol, 4-
OHT did not significantly alter Gal4 signals from the initial (t0) levels of Gal4 in no competitor 
controls. The increase in Gal4 after fifteen minutes of treatment with 4-OHT in the no competitor 
samples is not significantly different from the brief momentary increases in Gal4 signal observed at 
this time point for the DMSO treated control (Figure 2.3) or the effect of 17--estradiol in non-
inducing conditions (Figure 2.5). Importantly the Gal4 ChIP signal returns to the reference (t0) levels 
rather than increasing as much as four fold as is the case for 17--estradiol in galactose media (Figure 
2.4). When competitor Gal4 is present, treatment with 4-OHT leads to a rapid and significant loss of 
Gal4 at the GAL1 promoter. Indeed, most of the signal loss occurs by fifteen minutes with nearly two-
thirds of the initial (t0) signal gone. This rapid loss of Gal4 is consistent with the cycloheximide data 
and corresponds with the result of 17--estradiol when the Gal4 signal from yeast with competitor 
normalized to the Gal4 signal from yeast without the competitor (Figure 2.7). Therefore, I conclude 
that Gal4 does not lock onto chromatin, contrary to what was previously reported (Nalley et al. 2006). 
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 To confirm that the disappearance of Gal4 signal, representing the turnover of endogenous 
Gal4 from the GAL1 promoter, was indeed competitively displaced, I also monitored the arrival of 
competitor Gal4 to the same promoter when 4-OHT drives competition. The association of 
competitor Gal4 is measured by ChIP using antibodies directed against the N-terminal Myc-epitope 
tag. ChIP signals from this experiment were expressed as a percentage of Myc-ChIP signal obtained 
in a gal4 strain after one hour of competition with 4-OHT representing the maximal binding of 
competitor that should be observed in the competition experiments (Figure 2.8). This experiment 
demonstrates that the competitor rapidly and efficiently arrives to the GAL1 promoter even in the 
presence of endogenous Gal4. The appearance of competitor Gal4 at the promoter is indeed 
dependent on 4-OHT to start competition, as the Myc-ChIP signal in ethanol treated yeast is not 
significantly different than strains without competitor. Thus, the elements of a competition 
experiment are behaving appropriately: endogenous Gal4 signals are relatively unaffected by 
treatment with 4-OHT alone, and competitor Gal4 arrives at the target promoter at a rate that is not 
faster than the loss of endogenous Gal4. 
 
Discussion 
 I have shown that conclusion by the Kodadek group that Gal4, upon activation, stably 
associates with the GAL1 (Nalley et al. 2006) is misfounded, based in large part on competitive ChIP 
data demonstrating the stability of Gal4 with its target promoter. However, these data were based on 
experiments that used 17--estradiol to stimulate competition, which I discovered to have the 
unintended consequence of increasing the endogenous Gal4 signal when no competitor is present. I 
have normalized the Gal4 ChIP signal obtained in the presence of competitor Gal4 to that in which no 
competitor is present. Over the course of a competition assay this leads to a rapid decrease in Gal4 
present at the GAL1 promoter (Figure 2.7). This is consistent with competitive ChIP experiments 
using 4-OHT and ChIP data using cycloheximide treatment. These data, along with the arrival of 
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competitor Gal4 after treatment with 4-OHT, refute the conclusion that Gal4 stably occupies the 
GAL1 promoter. Instead, there is rapid turnover of Gal4 from chromatin, consistent with the expected 
behavior of a protein non-covalently bound to chromatin and does not preclude a possible role for the 
proteasome in regulating activator turnover at promoters undergoing active transcription. 
One of the unexpected and interesting findings from my work is that 17--estradiol increases 
the Gal4 ChIP signal. The cause is unknown —more Gal4 binding at the promoter, greater 
accessibility of the Gal4 epitope, or the establishment of a cellular environment that is more amenable 
to cross-linking are the most likely options. These are each testable, and could result in improved 
techniques to study Gal4 binding to DNA or even reveal new facets of what has been thought to be a 
well characterized activator. Also unknown are the proteins through which 17--estradiol functions to 
increase the Gal4 ChIP signal. Based on the previous characterization of OYE2 and OYE3 as genes 
encoding for estrogen binding proteins (Feldman et al. 1982; Burshell et al. 1984), and that yeast with 
the deletion of either or both genes are viable (Giaever et al. 2002; Odat et al. 2007), these two genes 
would be best candidates to begin to study how 17--estradiol regulates Gal4. 
However, as interesting as the surprise effect of 17--estradiol may be, I believe that the true 
significance of this work is clarifying confusion regarding the importance of activator turnover in 
transcription. Fluorescent microscopy has demonstrated that several activators are dynamic in their 
movement to and from the areas of active transcription (Hager et al. 2009). However, there are 
relatively few examples of studies that demonstrate the turnover of transcription factors that 
compliment and further validate the observations from live cell imaging. 
One of the notable examples of ChIP data demonstrating activator turnover is from the work 
of the Gannon laboratory studying, incidentally, the human estrogen receptor (hER) (Metivier et al. 
2003; Reid et al. 2003). The association of hER with its target promoters undergoes a cyclical 
pattern of binding and loss of binding that occurs roughly every forty minutes — substantially longer 
than the dynamic association of many activators observed using fluorescent labels, but still 
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demonstrating the point of activator turnover. Furthermore, these studies indicate that the dynamics of 
hER and its associated transcription is dependant on the proteasome.  
 I have not addressed the role of the UPS in the regulation of activator turnover, which is the 
important future direction of this work. The processes of Gal4 turnover as described by Muratani et al 
(Muratani et al. 2005) proceeds from phosphorylation of Gal4 to form phosphoisoform Gal4c, 
Mdm30 dependent ubiquitylation of Gal4c, and presumably proteolysis through the proteasome. 
Inhibiting these steps in trans is not the ideal approach because of significant off-target effects. The 
kinases required for Gal4c formation, Kin28 and Srb10, are important for the initiation of 
transcription in general. Mdm30 is so named for its regulation of mitochondrial distribution and 
morphology, which itself is necessary for respiratory competency and regulating galactose 
metabolism in multiple and potentially complicated processes (Dimmer et al. 2002; Fritz et al. 2003; 
Neutzner and Youle 2005; Durr et al. 2006; Escobar-Henriques et al. 2006; Cohen et al. 2008). 
Therefore, if the cis elements in Gal4 can be mapped and mutated that regulate Gal4 phosphorylation 
or ubiquitylation, I would use those forms of Gal4 to study the potential connection of activator 
turnover and regulation by the UPS. Such cis mutations for the phosphorylation of Gcn4 already exist 
(gcn4-3T2S) (Chi et al. 2001; Lipford et al. 2005) and therefore, establishing the competition assay in 
Gcn4 to study the importance of phosphorylation to activator turnover may prove to be a simpler and 
more rapid approach than mapping and mutating sites of phosphorylation in Gal4. 
 cis mutations of proteins that allow ubiquitylation but not proteolytic destruction are rare and 
poorly understood. Therefore, to study the contribution of the proteasome turnover demands the 
inhibition of the proteasome. However, the impact of the proteasome on Gal4 mediated transcription 
has itself been a controversial subject with one group finding that inhibiting the proteasome blocks 
transcriptional activation (Lipford et al. 2005) and a second group reporting no effect on transcription 
from proteasome inhibitors (Nalley et al. 2006). I believe that part of the difficulty exists because the 
level of proteasome inhibition that is achieved through conventional approaches is not adequate to 
study transcription with sufficient clarity. The development of a better approach to proteasome 
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inhibition is the purpose of the next chapter in my thesis, and the extension of this new strategy to 
studying transcription is discussed in chapters four and five. 
 I have demonstrated that there is indeed turnover of Gal4 on active promoters despite 
previous reports to the contrary (Nalley et al. 2006; Ferdous et al. 2007; Archer et al. 2008a; Archer 
et al. 2008b; Ferdous et al. 2008; Archer and Kodadek 2010) and as such there remains a possible 
important role for the UPS in regulating activators in the process of transcription. 
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Chapter Three: Increased Sensitivity to Proteasome Inhibition in S. cerevisiae 
Introduction 
In this chapter I will discuss my approach to studying the proteasome by combining chemical 
inhibitors with genetic inactivation of the proteolytic subunits. Small molecule inhibitors of the 
proteasome are powerful tools to study the importance and mechanisms of the ubiquitin proteasome 
system (UPS) in many diverse cell pathways. These drugs are important, not only as tools for 
research but also as naturally synthesized compounds and as useful pharmacological agents. 
Bortezomib (Velcade/PS-341) has become a valuable proteasome inhibitor for the treatment of 
multiple myeloma (Richardson et al. 2005). In addition to bortezomib, at least four other proteasome 
inhibitors (NPI-0052, carfilzomib/PR-171, CEP-18770, and MLN9708) are in phase I or phase II 
clinical trials for the treatment of various cancers. 
However, the typical approach of inhibiting the proteasome in S. cerevisiae has produced 
several instances in which the physiological effects are much smaller than would be expected given 
the importance of the proteasome in numerous cell processes such as cycle progression (King et al. 
1996; Zachariae and Nasmyth 1999), DNA repair (Krogan et al. 2004; Daulny and Tansey 2009), 
transcription (Auld and Silver 2006; Collins and Tansey 2006), protein quality control (Goldberg 
2003; Kostova and Wolf 2003), and organelle distribution (Campbell et al. 1994). For example, 
proteomic profiling of ubiquitylated proteins routinely uses proteasome inhibitors to stabilize 
ubiquitylated population of proteins. However, these proteome wide data sets of ubiquitylated 
proteins routinely fail to detect cyclins (Mayor et al. 2007), which are classically unstable proteins 
regulated by the UPS. This is consistent with the notion that inhibition of the proteasome through 
small molecule inhibitors is often incomplete. 
A second example in which the physiological response to proteasome inhibition is much 
smaller than one would expect a priori that inhibition of the proteasome would essentially halt 
growth. However, treatment with MG132 or bortezomib has little impact on cellular proliferation 
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(Lee and Goldberg 1996; Fleming et al. 2002). In contrast to the resistance of yeast to proteasome 
inhibition, inactivation of the only E1 activating enzyme, Uba1, rapidly terminates yeast growth 
(Ghaboosi and Deshaies 2007). 
If I am going to test the prediction that inhibiting the proteasome will inhibit activation of 
transcription then it will be useful to have a yeast strain in which the effects of proteasome inhibitors 
is unambiguous. 
My strategy to improve the responsiveness of S. cerevisiae to proteasome inhibition was to 
target all three of the proteasome proteolytic subunits: the 1 subunit Pre3 with its associated caspase-
like activity, the 2 subunit Pup1 with its associated trypsin-like activity, and the 5 subunit Pre2 
with chymotrypsin-like associated activity (Arendt and Hochstrasser 1997; Heinemeyer et al. 1997; 
Jager et al. 1999). Proteasome inhibitors have a marked bias towards a single proteolytic subunit, 
most commonly the chymotryptic subunit Pre2 (Lee and Goldberg 1996; Bogyo et al. 1998; Elofsson 
et al. 1999; Kisselev and Goldberg 2001; Kisselev et al. 2006; Groll et al. 2009). The bias of 
proteasome inhibitors towards the chymotryptic activity of the proteasome has not been typically 
considered a problem because the chymotryptic activity has been presumed to be the primary and 
rate-limiting step in proteasome mediated proteolysis (Kisselev et al. 2006). Although the 
chymotryptic activity is commonly considered to be the most significant proteolytic activity, the other 
two proteases presumably make important contributions in the cell. Analysis of the mammalian 
proteasome revealed a differential requirement for each proteasome subunit depending on the 
substrate (Kisselev et al. 2006). It would be very surprising if the same were not true for the yeast 
proteasome too, considering the similarity of the yeast and mammalian proteasomes. Therefore I have 
combined the chemical inhibition of the proteasome with genetic inactivation of the two non-
chymotryptic proteasome proteases. 
Genetically inactivating the proteasome proteases is straightforward —each protease depends 
on a single catalytic threonine. Although the genes encoding each proteasome protease are all 
essential (as are most other proteasome genes (Giaever et al. 2002)) the loss of any one catalytic site 
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is not lethal. In fact yeast without the PUP1 and PRE3 catalytic threonines are also viable making it 
possible to have the proteasome operate entirely on through chymotryptic activity, the activity 
towards which most proteasome inhibitors are directed against. Therefore, treatment with an inhibitor, 
such as MG132, should acutely shutdown the remaining proteolytic activity of the proteasome. 
One other necessary step to generate yeast that are hyper-sensitive to proteasome inhibition is 
to ensure adequate concentration of MG132 in the cell. The effective intracellular concentration of 
proteasome inhibitors is not very high in wild type yeast for three main reasons: ineffective 
permeability of the inhibitors against the yeast cell wall (Lee and Goldberg 1996; Liu et al. 2007), 
efflux of the inhibitors under the control of pleiotropic drug resistance genes (Fleming et al. 2002), 
and up regulation of the proteasome subunits through the transcription activator Rpn4 in response to 
proteasome inhibition (Xie and Varshavsky 2001; Fleming et al. 2002; Ju et al. 2004; Wang et al. 
2008; Wang et al. 2010). Increasing the effective concentration by deleting a single pleiotropic drug 
response gene, PDR5, is sufficient to sensitize the yeast to many proteasome inhibitors and permits 
future study of the transcription of the proteasome genes themselves, which if transcription activation 
typically depends on proteolysis represents an interesting counter example of a transcription activator 
that is activated by inhibiting proteolysis. 
 
Experimental Procedures 
Yeast Strains 
Strains used in this study are listed in table 3.1. The strains MHY1177 and MHY178 (Arendt 
and Hochstrasser 1999), were a gift from Mark Hochstrasser. I deleted PDR5 from these strains using 
gene replacement with KanMX6 by homologous recombination using sequences flanking the PDR5 
ORF. I synthesized the knockout cassette by PCR using pYM1 (Knop et al. 1999) as a template, and 
transformed the cassette as described by Gietz and Woods (Gietz and Woods 2002). Correct targeting 
was validated by PCR. The resulting strains are GAC201 (PUP1PRE3pdr5) and GAC202 
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(pup1pre3pdr5). For -arrest experiments, GAC201 and GAC202 were converted to the a mating 
type by expressing the HO endonuclease from a URA3 selectable vector (Ycp50-HO 
(Krishnamoorthy et al. 2006); gift from Shelly Berger) followed by counter-selection with 5-FOA 
(US Biological). I verified mating type by testing growth of bar1 yeast (RC634 (Chan and Otte 
1982); gift from Brehon Laurent) in the presence of patches of potentially switched yeast and by 
growth sensitivity to -factor (Zymo Research). I confirmed that the MATa and MATa yeast had 
similar growth rates and flow cytometric profiles following nocodazole block and release. 
 
Table 3.1: Yeast Strains Used 
Strain Genotype Source 
BY4742 
pdr5 
Mat his31 leu20 lys20 ura30 pdr5::KanMX6 This study 
MHY1177 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre3::HIS3 pup1::leu2::HIS3 [pRS317-PUP1] 
[YCplac22-PRE3] gal- 
(Arendt and 
Hochstrasser 
1999) 
MHY1178 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre3::HIS3 pup1::leu2::HIS3 [pRS317-pup1T30A] 
[YCplac22-pre3T20A] gal- 
(Arendt and 
Hochstrasser 
1999) 
GAC201 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre32::HIS3 pup1::leu2::HIS3 [pRS317-PUP1] 
[YCplac22-PRE3] gal-- 
This study 
GAC202 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre3::HIS3 pup1::leu2::HIS3 [pRS317-pup1T30A] 
[YCplac22-pre3T20A] gal- 0 
This study 
GAC201a Mata his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre3::HIS3 pup1::leu2::HIS3 [pRS317-PUP1] 
[YCplac22-PRE3] gal- 
This study 
GAC202a Mata his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre3::HIS3 pup1::leu2::HIS3 [pRS317-pup1T30A] 
[YCplac22-pre3T20A] gal-  0 
This study 
RC634 Mata rme1 ade2-1 ura1 his6 met1 can1 cyh2 sst1-3 (Chan and Otte 
1982) 
RJD3269 Mata can1-100 leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1 
uba1::KanMX6 [pRS313-uba1-204-His] 
(Ghaboosi and 
Deshaies 2007) 
 
Table 3.2 Plasmids Used 
 
Plasmid Features Source 
pYM1 KanMX6 tag (Knop et al. 1999) 
Ycp50-HO HO mating type switching (Krishnamoorthy 
et al. 2006) 
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Proliferation assay 
I grew S. cerevisiae cultures at 30°C from an A600 nm
 0.2 in 10 ml YPAD with either 50 M 
MG132 (American Peptide) or an equivalent volume DMSO (Sigma). At the indicated time points 
following treatment, I measure the A600 nm from 1 ml of each sample. 
For the MG132 titration experiment, 10 ml YPAD cultures were started at an A600 nm 0.5 with 
the indicated concentrations of MG132. Following twenty-four hours of treatment I measured the A600 
nm from 1 ml of each sample. IC50 was approximated by first calculating the percent inhibition of the 
maximum possible inhibition (assuming no change in absorbance is that maximum) and then 
calculating the best fit curve (least squares) of the equation I = (Max · MC) ÷ (IC50 + MC) to the data 
where I is the percent inhibition for a given concentration of MG132 (MC) and Max is maximum 
inhibition. 
 
Cell cycle assays 
GAC201a and GAC202a were arrested in G1 using 30 M -factor in 10 ml YPAD cultures 
for two hours at 25°C. Samples were then treated with an additional 15 M -factor and 50 M 
MG132 (or equivalent volume of DMSO) for another hour at 25°C. I collected 1ml of culture for the 
“time zero” (t0) sample. I released the remaining culture from arrest by washing twice with YPAD 
before growing as a 9 ml YPAD culture with 50 M MG132 or equivalent volume DMSO at 30° C. I 
collected 1 ml of culture at each of the indicated time points. 
I arrested GAC201 and GAC202 in G2/M by treating 10 ml YPAD cultures with 150 g 
nocodazole (Sigma) for 90 minutes at 30°C. I then treated the cultures with an additional 75 g 
nocodazole and 50 M MG132 (or equivalent volume DMSO) for an hour at 30°C. I collected 1ml of 
culture for the “time zero” (t0) sample. I released the remaining culture from arrest by washing twice 
with YPAD before growing as a 9 ml YPAD culture with 50 M MG132 or equivalent volume 
DMSO at 30° C. I collected 1 ml of culture at each of the indicated time points. 
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From each of the arrested and released samples and from asynchronously growing yeast 
populations, I resuspend the cells in 70% ethanol and fixed at 4°C overnight. These cells were then 
washed with water, treated for 12 hours at 37°C with 1 g RNase, DNase free (Roche), sonicated, 
treated for 2 hours at 42°C with 500 g proteinase K (Roche), and stored in a 50 mM Tris-HCl (pH 
7.5) solution. 1 x 106 cells were diluted in 1 ml of SYBR gold solution (Invitrogen). I counted cells 
and DNA content using a LSR II cell analyzer (BD Biosciences). 
 
Ubiquitylation assay 
I grew 15 ml YPAD cultures treated with 50 M MG132 for the indicated time. From these 
cultures I extracted proteins by boiling in EZ buffer (60 mM Tris-HCl pH 6.8, 10% glycerol, 2% 
SDS, 2% 2-mercaptoethanol). I used the Bio-Rad protein assay to determine protein concentration to 
run 50 g protein on 8% polyacrylamide gels. These gels were transferred onto a 0.45 M 
nitrocellulose membrane (Whatman). 1:1,000 anti-ubiquitin antibody (MAB1510, Millipore) and 
1:15,000 anti-mouse-HRP (GE Health Care). I checked that equivalent amounts of protein were 
loaded using Ponceau S staining of the membrane. 
 
Results 
Combined genetic and chemical inhibition of the proteasome prevents cell proliferation 
Although proteasome inhibitors are useful tools to study the mechanism and biology of the 
proteasome, I have been concerned that the physiological response of S. cerevisiae to MG132 is too 
subtle. For example, I grew BY4742 yeast with a deletion of the pleiotropic drug response gene 
PDR5 in the presence or absence of 50 M MG132, the typical concentration of proteasome inhibitor 
used in S. cerevisiae (Figure 3.1). Under these conditions the proliferation of yeast does not halt. 
Treatment with MG132 did slow the initial growth for the first eight hours of treatment after which, 
although there is nearly a two hour delay between when DMSO treated yeast reach a given A600 nm 
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and when MG132 treated yeast reach that optical density, the shape of the growth curves a very 
similar indicating similar rates of proliferation after eight hours of MG132 treatment. Most 
significantly, this treatment did not halt growth. Similar results have been observed in MG132 treated 
yeast in increased drug uptake through ISE1 deletion (Lee and Goldberg 1998) or in bortezomib 
treated pdr5 yeast (Fleming et al. 2002). However, inactivation of the first step of the UPS, the E1 
activating enzyme uba1-204, results in rapid and dramatic growth arrest (Ghaboosi and Deshaies 
2007), supporting the conclusion that MG132 alone is insufficient to fully inhibit the proteasome. 
Therefore, I developed a new strategy combining chemical inhibition of the chymotryptic 
subunit, Pre2, with genetic inactivation of the other two proteolytic proteasome subunits, Pup1 and 
Pre3, for the purpose of improving proteasome inhibition. The new strain with pup1-T30A, pre3-
T20A mutations and deletion of PDR5 (pup1pre3pdr5) proliferated slower than its related 
PUP1PRE3pdr5 strain (Figure 3.2, compare the blue shaded squares to the green shaded circles), 
consistent with the previous report that inactivating Pup1 and Pre3 by replacing those catalytic 
threonines to alanines (Arendt and Hochstrasser 1999). (This effect may be due to this strain being a 
petite mutant as discovered by genome-wide analysis of transcription, see Chapter Five). 
Furthermore, in the context of the pup1-T30A and pre3-T20A mutations, the effect of MG132 
inhibiting proliferation was striking as there was comparatively little increase in A600 nm over the 
sixteen hours of treatment (Figure 3.2, orange solid circles). These findings support two conclusions. 
First, the standard use of the proteasome inhibitor MG132 does not fully inhibit the proteasome. 
Second, although the chymotryptic activity is considered the most important proteasome protease and 
as such is the best characterized and most commonly targeted of the proteasome subunits, the other to 
proteolytic enzymes make important contributions to the cell —at least as measured by proliferative 
growth. 
I tested the dose sensitivity of the pup1pre3pdr5 to MG132 to determine if the growth defects 
observed at 50 M concentrations of MG132 represented an appropriate level of inhibitor to use 
(Figure 3.3). Titration of MG132 from 10 M to 100 M concentrations did not significantly change 
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proliferation of PUP1PRE3pdr5 yeast over the course of one day of treatment. A similar result in a 
ise1 strain was previously reported with concentrations extending to 200 M (Lee and Goldberg 
1998). However, in the pup1pre3pdr5, the change in A600 nm after twenty-four hours of treatment was 
significant. With as little as 10 M MG132 there was a marked decrease in cell proliferation that 
rapidly decreased to an average of two cell divisions in a twenty-four hour period. The titration of 
MG132 over this scale permits for the calculation of an approximate IC50 for MG12 in the 
pup1pre3pdr5 strain as rough 24 M. This indicates 50 M MG132 is a reasonable level of 
proteasome inhibitor to target the pup1pre3pdr5 proteasome.  
 
Inhibition of the proteasome impairs progression through the cell cycle 
 If treatment of yeast with MG132 in the genetic context of pup1-T30A and pre3-T20A 
mutations results in substantial decrease in grow rates of S. cerevisiae, then a reasonable question to 
address is what stage or stages of the cell cycle were inhibited by MG132. Some of the classic 
examples of protein ubiquitylation and destruction involve the G1 and mitotic cyclins (King et al. 
1996; Zachariae and Nasmyth 1999), which would suggest multiple stages of the cell cycle 
responsible for the growth arrest for pup1pre3pdr5 cells treated with MG132. Likewise, inactivating 
the E1 ubiquitin activating enzyme uba1-204 arrests cells throughout the cell cycle (Ghaboosi and 
Deshaies 2007). To test that cell cycle arrest occurred at multiple steps in the cell cycle I labeled the 
DNA of yeast using SYBR gold and counted the DNA content per cell using flow cytometry. 
I studied the effects of proteasome inhibition on asynchronous populations after one hour of 
treatment with proteasome inhibition (Figure 3.4). Comparing cytometric profiles (Figure 3.4 A) and 
counts of cell with 1n (G1), 2n (G2/M), or intermediate (S) levels of DNA (Figure 3.4 B), I do not 
observe any dramatic changes. The loss of Pup1 and Pre3 in pup1pre3pdr5 may lead to a decrease in 
the population of cells in S phase regardless of treatment with MG132. Additionally, there may be an 
increase in the 1n DNA content cell population of pup1pre3pdr5 yeast treated with DMSO compared 
to PUP1PRE3pdr5 yeast, and a corresponding decrease in 2n DNA content. But with this effect not 
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reproduced in MG132 treated yeast, these findings may not be significant. In general analysis of the 
asynchronous population does not reveal any particular phase of the cell cycle in which the 
proliferative arrest occurs. 
Next, I synchronized the yeast populations by arresting in G2/M phase using nocodazole 
(Figure 3.5). Measuring the changes in DNA content after release from nocodazole can reveal the 
ability of yeast to exit past this stage of the cell cycle. Once again, in the PUP1PRE3pdr5 yeast, 
treatment with MG132 has negligible effect on cell cycle progression. In pup1pre3pdr5 yeast, loss of 
the Pup1 function or Pre3 function or both leads to slower progression out of 2n DNA content and 
into 1n DNA content. Treatment with MG132 seems to result in either slightly slower G2/M exist in 
pup1pre3pdr5 than treatment with DMSO or a relative flat progression through the cell cycle. 
I also synchronized the yeast populations in G1 with -factor mating pheromone (Figure 3.6). 
When released from -factor induced arrest, treatment of PUP1PRE3pdr5 yeast with MG132 
produced a slight lag in rate at which cells progressed from G1 into later stages of the cell cycle. In 
contrast, loss of Pup1 and Pre3 function in DMSO treated pup1pre3pdr5 yeast had a higher initial 
level of cells with 1n DNA content, but as the shape of the curve for progressive loss of 1n DNA 
content is similar to DMSO treated PUP1PRE3pdr5 (Figure 3.6 B) the rate of cell cycle progression 
from 1n to 2n DNA content is not dependent on Pup1 and Pre3 activity. Inhibition of the 
chymotryptic site with MG132 and loss of Pup1 and Pre3 function combine to pause the cells mostly 
in G1 but there is a fraction of cells that arrested in G2 instead (23.8 ± 0.7%; 95% CI). 
These data are consistent with the notion that impairment of the UPS in general, and 
proteolysis in particular, prevents the efficient progression through the cell cycle. Furthermore, the 
progression of through the various stages seem to highlight not only the synergistic effects of 
inhibiting the chymotryptic activity in pup1pre3pdr5 yeast but also the different relative effects of 
MG132 and loss of Pup1 and Pre3 activity. Cells released from -arrest were not greatly inhibited by 
loss of Pup1 and Pre3 function alone but were affected by MG132 treatment in PUP1PRE3pdr5 yeast 
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(Figure 3.6). In contrast, treatment of MG132 alone had negligible impact on the release from 
nocodazole-induced block but pup1pre3pdr5 exited nocodazole arrest more slowly (Figure 3.5). 
 
Inhibition of the proteasome accumulates ubiquitylated proteins 
Presumably, inhibiting the proteasome by targeting all three of its proteolytic activities delays 
proliferation and progression through the cell cycle by stabilizing unstable protein targets. It should, 
therefore, be possible to detect the accumulation of high molecular weight ubiquitylated proteins 
when the proteasome is inhibited at all three of its proteolytic sites, to an extent greater than that 
observed by treating with MG132 alone or by inactivating PUP1 and PRE3 genetically. Compared to 
untreated PUP1PRE3pdr5 yeast, the loss of the tryptic and caspase-like activity increases the 
detection of ubiquitin conjugated proteins by western blot using anti-ubiquitin antibodies (Figure 3.7 
compare lanes 1 and 6). Treating yeast with MG132 increases the accumulation of ubiquitylated 
proteins in PUP1PRE3pdr5 yeast, which is often used demonstrate the efficacy of MG132 treatment 
in yeast. However MG132 treatment increases the accumulation of ubiquitylated proteins and to a 
greater extent in pup1pre3pdr5 strains than in PUP1PRE3pdr5 (Figure 3.7). Therefore, in addition to 
the chymotryptic activity, at least one of either the caspase-like or tryptic activities of the proteasome 
contributes to the normal processing of the ubiquitin conjugated proteins. 
 
Discussion 
 I have developed a new strain of yeast with increased sensitivity to proteasome inhibitors by 
combining chemical inhibition of the chymotryptic site with genetic inactivation of the tryptic and 
caspase-like subunits to simultaneously target all three of the proteasome proteases. This approach 
elicits more dramatic effects than treatment with MG132 alone, and establishes that previous work 
with proteasome inhibitors need to be interpreted carefully because the use of proteasome inhibitors 
does not necessarily mean that the proteolytic ability of the proteasome is fully shutdown. Failure to 
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detect significant changes after treatment with a proteasome inhibitor should not be interpreted as 
proof that there is not a proteolytic role for that observed process. I have shown that there is in fact 
significant proteolytic ability within at least one, if not both, of the Pup1 and Pre3 subunits. 
Presumably it is this remaining proteolytic activity that prevents MG132 treatment alone from 
arresting proliferation. Indeed, the loss of Pup1 and Pre3 activity has a significant impact on yeast 
proliferation, cell cycle progression, and accumulation of ubiquitylated species. Because I have 
studied the loss of both subunits at once, the relative contribution of each subunit remains an 
important area for future investigation. 
 For my purposes I see this strain as valuable tool for studying the intersection of the 
proteasome and transcription. It is not a useful strain to study GAL inducible genes, because this 
strain is galactose negative and is not rescued by expression of wild-type GAL2, a common basis for 
galactose negative laboratory strains (Winston et al. 1995). However, with many other inducible 
genes that are potentially regulated by the UPS (Lipford and Deshaies 2003; Muratani and Tansey 
2003; Lipford et al. 2005), this strain is a valuable resource to study transcription. 
This new strain of yeast establishes a valuable resource for the yeast community. I have only 
begun to highlight the impact of the proteasome on proliferation, cell cycle progression, and the 
stability of ubiquitylated proteins. The later observation suggests that this strain might be particularly 
amenable to proteomic analysis of ubiquitylated proteins. The absence of classically unstable 
proteins, such as cyclins, from ubiquitylated protein data sets is a striking example of the 
incompleteness of these data sets. 
 The combination of a demonstrable growth defect and ability to use lower concentrations of 
proteasome inhibitor make this strain amenable to using plates to study the effects of proteasome 
inhibitors such as MG132, YU101, epoximycin, and carfilzomib (personal communication, Tara 
Gomez and Raymond Deshaies). One application of these plates is to screen other genes or chemical 
compounds that enhance or suppress the ability to grow in the presence of proteasome inhibitors. The 
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use of other proteasome inhibitors —YU101, epoximycin, and carfilzomib —demonstrates that this 
strain also has increased sensitivity to other chymotryptic-biased inhibitors. 
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Chapter Four: Inhibition of the Proteasome Inhibits Activation of Certain Genes 
Introduction 
In this chapter I will describe the effects of proteasome inhibition on the ability to activate 
transcription from four different model loci. If proteolytic turnover of activators is important for 
transcriptional activation then inhibiting the proteasome should have substantial impact on the ability 
to drive transcription. Although many groups examined the impact of proteasome inhibition on 
transcription (Kawazoe et al. 1998; Wallace and Cidlowski 2001; Deroo et al. 2002; Fleming et al. 
2002; Mitsiades et al. 2002; Dembla-Rajpal et al. 2004; Dennis et al. 2005; Yew et al. 2005; Kinyamu 
and Archer 2007; Lassot et al. 2007; Tirard et al. 2007; Kinyamu et al. 2008; Middledorp et al. 2009), 
the resulting data is often contradictory resulting in continued debate regarding the importance of 
proteolysis on transcription. Gal4 represents a microcosm of this debate; two separate groups have 
arrived at diametrically opposed conclusions regarding the importance of proteasome-mediated 
proteolysis on the activation of transcription (Lipford et al. 2005; Nalley et al. 2006). Both groups 
studied the activation of the same gene, GAL1, and used the same proteasome inhibitor, MG132. 
Whereas Lipford et al found that GAL induction was lost when yeast were treated with MG132 
(Lipford et al. 2005), Nalley et al reported that inhibition of the proteasome had negligible effect on 
transcription of GAL genes (Nalley et al. 2006). I have since examined this question myself to 
determine which result I have the most confidence in to build my model of how the proteasome 
regulates transcription activators. 
In light of my work developing a strain with increased sensitivity to proteasome inhibition 
(see Chapter Three), the inability to detect an impact on transcription after treatment with a 
proteasome inhibitor, such as MG132, is not compelling evidence that the proteasome is dispensable 
for transcription. Increasing the overall sensitivity of yeast to proteasome inhibitors might also 
increase the degree to which transcription is affected by proteasome inhibitors. Therefore, I 
investigated the impact of proteasome inhibition in the context of this strain. Both MHY1177 and 
MHY1178, which were the parental strains to my PUP1PRE3pdr5 (GAC201) and pup1pre3pdr5 
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(GAC202) are galactose negative and not made galactose positive by expression of wild-type GAL2, a 
common cause for the galactose negative phenotype in laboratory strains of S. cerevisiae (Winston et 
al. 1995). Although these strains were unsuitable to further analyze Gal4 dependent transcription in 
the presence of increased inhibition of the proteasome, many other active genes were available to 
study. I chose ARG1 (regulated by the activator Gcn4 (Swanson et al. 2003; Yoon et al. 2004; Govind 
et al. 2005; Kim et al. 2005; Qiu et al. 2005)) and INO1 (regulated by the heterodimeric activator 
Ino2/Ino4 (Lopes and Henr 1991; Lai and McGraw 1994; Nikoloff and Henry 1994; Graves and 
Henry 2000; Shirra et al. 2005; Esposito et al. 2010)) as genes whose induction was previously 
reported as sensitive to MG132 (Lipford et al. 2005) but had the same pallor of doubt cast over it as 
for the finding that GAL1 is sensitive to proteasome inhibition. I also selected CHA1 for my analysis, 
a gene that had not previously been analyzed for its dependence on proteasome and represents a 
different class of activated genes in that its regulation depends critically on the movement of a 
positioned nucleosome at the TATA box (Petersen et al. 1988; Bornaes et al. 1993; Holmberg and 
Schjerling 1996; Moreira and Holmberg 1998; Zawadzki et al. 2009). 
 
Experimental Procedures 
 Yeast Strains 
 Strains used in this study are listed in Table 4.1. I deleted the PDR5 gene from BY4742 using 
gene replacement with KanMX6 by homologous recombination using sequences flanking the PDR5 
ORF. I synthesized the knockout cassette by PCR using pYM1 as a template (Knop et al. 1999), and 
transformed the cassette as described by Gietz and Woods (Gietz and Woods 2002). Correct targeting 
was validated by PCR. Similarly I deleted PDR5 in W303-1a using gene replacement with a TRP1 
cassette using pRS404 as template for PCR (Sikorski and Hieter 1989). The preparation of GAC201 
(PUP1PRE3pdr5) and GAC202 (pup1pre3pdr5) is described in the methods section of Chapter 
Three. 
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 I induced GAL gene expression by addition of 20% (w/v) aqueous solution of galactose to 
yeast grown in CSM 2% raffinose for a final concentration of 2% galactose. Unless otherwise 
indicated, samples were collected one hour post galactose induction. I inhibited the proteasome by 
treating with 50 M MG132 for half an hour prior to induction to be consistent with the methods 
previously used to study the affect of MG132 on transcription (Lipford et al. 2005; Nalley et al. 
2006). 
I induced ARG1 expression by transferring yeast grown in YPAD to CSM lacking histidine 
(Formedium) and supplemented with 100 mM 3-aminotriazole (3-AT) (Sigma). Non-induced ARG1 
controls were transferred from YPAD to CSM and mock treated with a volume of water equivalent to 
3-AT used to induce ARG1. I induced INO1 by rinsing yeast grown in YPAD with water and then 
transferring the yeast to CSM lacking inositol (Formedium). Non-induced INO1 controls were 
similarly rinsed and then transferred into CSM. I induced CHA1 with the addition of 1 mg/ml L-
serine (Formedium). ARG1, INO1, and CHA1 induction proceeded for 90 minutes before collecting 
RNA for expression analysis or formaldehyde cross-linking for ChIP analysis. I inhibited the 
proteasome by treating with 50 M MG132 at the time of induction. 
 
Table 4.1: Yeast Strains Used 
 
Strain Genotype Source 
BY4741 pdr5 Mata his31 leu20 lys20 ura30 pdr5::KanMX6 This study 
W303-1a pdr5 Mata leu2-3,112 trp1-1, can1-100, ura3-1, ade2-1, his3-
11,15, ypb1-1 pdr5::TRP1 
This study 
GAC201 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre32::HIS3 pup1::leu2::HIS3 [pRS317-PUP1] 
[YCplac22-PRE3] gal- 
This study 
GAC202 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pre32::HIS3 pup1::leu2::HIS3 [pRS317-pup1T30A] 
[Ycplac22-PRE3] gal-  0 
This study 
 
Table 4.2: Plasmids Used 
 
Plasmid Features Source 
pYM1 KanMX6 selectable marker (Knop et al. 1999) 
PRS404 TRP1 selectable marker (Sikorski and 
Hieter 1989) 
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RNA extraction and analysis 
I collected RNA from 15 ml of yeast at mid-log phase growth (A600 nm = 0.6 – 1.0) using a 
Hot Phenol RNA extraction method (Collart and Oliviero 1993). Cells were lysed in RNA extraction 
buffer (50 mM sodium acetate (pH 4.8), 0.5% SDS, and 10 mM EDTA) and an equal volume of acid 
(pH 4.3) phenol (Sigma) by incubating at 65 °C for one hour. Samples were chilled on ice for five 
minutes, centrifuged for five minutes, and the aqueous phase was collected for purification through 
another extraction with acidic (pH 4.3) phenol and an extraction with 25:24:1 
phenol:chlorofom:isoamyl alcohol (Sigma). Samples were precipitated in ethanol for less than 20 
minutes at –20°C. RNA was resuspend in nuclease free water. Contaminating DNA was removed 
with DNase I (invitrogen). 1 g of RNA was used for first strand cDNA synthesis with SuperScript II 
reverse transcriptase (invitrogen). 
 I quantified cDNA by qPCR with SYBR fast PCR mix (Kapa Biosystems). Expression was 
calculated relative ACT1 by 2ACT1-GOI where ACT1 is the signal from the ACT1 ORF (ACT1q1 and 
ACT1q2 oligonucleotides) and GOI is the gene of interest. GAL1 gene signals in induction time 
course experiments were normalized setting the maximum signal to 1000 arbitrary units to minimize 
the noise of experiment-to-experiment variation in GAL1 induction. (1000 was selected because the 
median expression of GAL1 was 951 fold above ACT1 expression). 
 
Chromatin Immunoprecipitation 
 For ChIP I fixed 50 ml of yeast culture with 1.5 ml paraformaldehyde solution (37% (w/v) 
paraformaldehyde (Sigma) in 1x phosphate buffer solution (PBS) and 0.2% 10N KOH) for 30 
minutes. Cross-linking was stopped with 3 ml 2.5 M glycine for 5 minutes at room temperature 
before washing the cells with PBS. Cells were lysed in 800 l lysis buffer (50 mM HEPES (pH 7.5), 
15 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% SDS, 0.1% DOC) by bead beating. Cell lysates 
were sonicated to approximately 500 base pairs median fragments. Chromatin was incubated with 
1:1000 dilution of anti-Rpb3 antibody (1Y26, Neoclone) overnight at 4 °C followed with an hour 
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incubation at 4 °C with a 1:100 dilution of rabbit anti mouse IgG antibody (invitrogen) before 
pulldown with protein A sepharose beads (GE Healthcare). Immunoprecipitated chromatin bound to 
protein A sepharose beads was washed in IP buffer (50 mM HEPES (pH 7.5), 15 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 0.1% SDS, 0.1% DOC), high salt buffer (50 mM HEPES (pH 7.5), 50 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% DOC), lithium-DOC buffer (10 mM Tris-
HCl (pH 8.0), 1 mM EDTA, 0.25 M LiCl, 5% NP-40 alternative, 5% DOC), and twice with 10x Tris-
EDTA (TE) buffer (10 mM Tris-HCl (pH 8.0), 100 mM EDTA) before elution for 20 minutes in 
elution buffer (100 mM NaHCO3, 1% SDS). Eluted chromatin and input chromatin were reverse-
cross-linked overnight at 65 °C. Samples were treated with 1.5 mg proteinase K (Roche). DNA was 
purified with a phenol:chloroform extraction and precipitated in ethanol and stored in TE buffer. 
 I quantified the amount of DNA that came down in the immunoprecipitation by qPCR with 
SYBR fast PCR mix (Kapa Biosystems). I calculated enrichment as described by Ezhkova et al 
(Ezhkova and Tansey 2004). Automatically-derived cycle thresholds were obtained from triplicate IP 
samples for both the amplicon of interest (CIPA) and a reference locus (CIPR) as well as corresponding 
threshold values from input chromatin (CINA and CINR respectively). Fold enrichment is then 
calculated as [2(IPR-IPA)] ÷ [2(INR-INA)]. I used V(L) intergenic sequence as my reference to normalize for 
Rpb3 binding. 
 
Results 
GAL gene induction is impaired by proteasome inhibition 
 Given my interest in the connection between the proteasome and Gal4 function and in light of 
the controversy regarding the effect of proteasome inhibition on GAL1 induction (Lipford et al. 2005; 
Nalley et al. 2006) I have analyzed the expression of GAL1 genes in the presence or absence of the 
proteasome inhibitor MG132. Following the same protocol as both Lipford et al and Nalley et al of 
inhibiting the proteasome with 50 M MG132 half an hour prior to induction with galactose, I 
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observed greater than five-fold inhibition of GAL1 induction compared to DMSO control samples 
after an hour of induction (Figure 4.1). The effects of proteasome inhibition on transcription are 
detectable as early as 15 minutes post-induction (students t-test p = 0.07; n =5) and continue to 
increase over the course of the hour. This result demonstrates a significant dependence on 
proteasome-mediated proteolysis in the activation of GAL1 contrary to the report of Nalley et al. 
To alleviate concerns that MG132 may affect GAL1 expression in a strain specific context I 
also tested the response of GAL1 expression to MG132 in the yeast strain W303-1a pdr5, whereas 
previously I worked with BY4741 pdr5 (Figure 4.2). Once again I detected approximately five-fold 
decrease in transcription in both strains, ruling out differences between these two strains. 
 I decided to determine if the effects of MG132 inhibition were limited to just GAL1 or 
extended to other strongly induced Gal4 regulated genes. Therefore, I measured the transcription at 
GAL2, GAL7, and GAL10 in addition to GAL1 (Figure 4.3). All genes, despite having different levels 
of expression relative to each other, demonstrated a typically five-fold decrease in activation when 
treated with MG132. Therefore, I am convinced of the importance of the proteolytic ability of the 
proteasome to strongly induce Gal4 dependent transcription sharp contrast to the report of Nalley et al 
(Nalley et al. 2006). 
 
Proteasome Inhibition of Transcription Activation Is Sensitive to the Activity of Pup1 or Pre3 or 
Both Subunits 
 The parental strains to make PUP1PRE3pdr5 and pup1pre3pdr5 were galactose negative. 
Therefore, to use PUP1PRE3pdr5 and pup1pre3pdr5 to study gene activation I looked at the 
transcriptional effects of proteasome inhibition on the activation several other genes. ARG1 
transcription is induced, along with several other genes, by amino acid starvation through the 
transcription activator Gcn4 (Swanson et al. 2003; Yoon et al. 2004; Govind et al. 2005; Kim et al. 
2005; Qiu et al. 2005). This activator, like Gal4 is both well characterized and unstable during 
conditions associated with its function (Meimoun et al. 2000; Chi et al. 2001; Shemer et al. 2002; 
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Lipford et al. 2005). Like Gal4, Gcn4 is phosphorylated two kinases associated with the transcription 
initiation complex, Kin28 and Pho85. Gcn4 is ubiquitylated by the essential E3 ligase Cdc4 and 
inactivation of the temperature-sensitive version of Cdc4 by shifting to the non-permissive 
temperature results in the loss of transcription in response to amino acid starvation (Lipford et al. 
2005). Furthermore, inhibition of the proteasome also prevented induction of Gcn4 target genes. 
However, based on the debate over GAL1 dependence on the proteasome this later finding has been 
doubted (Kodadek 2010). I hypothesized that this was the type of situation that would benefit from 
increased sensitivity to proteasome inhibition. I used the histidine analogue 3-AT to induce ARG1 
transcription in both PUP1PRE3pdr5 and pup1pre3pdr5 strains (Figure 4.4). In the essentially wild-
type proteasome context of PUP1PRE3pdr5 I find a non-statistically significant decrease in ARG1 
activation when yeast were treated with MG132 (t-test p = 0.111; n = 5). When I examined ARG1 
activation in pup1pre3pdr5 yeast treated with MG132 not only was there a significant inhibition of 
transcriptional activation but the levels of ARG1 expressed were now comparable to the basal level of 
expression consistent with failure to induce the ARG1 gene. I conclude the ARG1 activation is 
dependent on the proteasome activity. Whereas in my PUP1PRE3pdr5 yeast I could find a significant 
loss of ARG1 expression, the combined activity of MG132 and loss of Pup1 and Pre3 yielded 
unambiguous results consistent with the potential of this strain to more clearly study the connection 
between proteasome-mediated proteolysis and transcription. 
 To begin to determine where the loss of proteasome function was regulating transcription I 
looked at the recruitment of RNApolII to the early ORF of ARG1. If the proteasome was necessary 
for the signaling pathway upstream of Gcn4 or for the initiation of transcription then the loss of 
proteasome function should lead to the loss of RNApolII recruitment. Conversely, defects in 
elongation should still permit for significant detection of RNApolII at the early ORF. I performed the 
ChIP with antibodies against the Rpb3 subunit of RNApolII and I observed recruitment of RNApolII 
to the ARG1 locus in PUP1PRE3pdr5 yeast only when yeast were treated with 3-AT (Figure 4.5). 
MG132 did not affect this recruitment, consistent with the inability to detect a significant loss if 
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ARG1 transcription. In pup1pre3pdr5 yeast, I detected lower Rpb3 ChIP signals with in 3-AT 
induction conditions than what I observed in the PUP1PRE3pdr5 strain. This is in contrast to the 
level of transcripts observed in these strains. Nevertheless, treatment with MG132 further decreases 
the level of RNApolII at ARG1 to levels that are now similar to RNApolII when the ARG1 
transcription is off. These data are consistent with impairment in transcription initiation as a result of 
impairing the proteolytic function of the proteasome. 
 I looked at a different locus, INO1, to begin to gauge how general common sensitivity of 
transcription activation to proteasome inhibition in S. cerevisiae. The INO1 gene is activated through 
the heterodimeric activator Ino2 and Ino4 in response to depletion of inositol (Lopes and Henr 1991; 
Lai and McGraw 1994; Nikoloff and Henry 1994; Graves and Henry 2000; Shirra et al. 2005; 
Esposito et al. 2010). In PUP1PRE3pdr5 yeast, treatment with MG132 does not inhibit activation 
and, if anything, elevates the level of INO1 expression (Figure 4.6). In contrast, the loss of at least on 
of the activities of Pup1 and Pre3 hinders the activation of INO1. Furthermore, consistent with 
synergistic effect of MG132 treatment with the loss of Pup1 and Pre3 proteolytic activities, INO1 
transcription becomes even lower, suggesting a critical dependence on proteasome function for the 
activation of this gene. The levels of RNApolII recruitment to INO1 display a pattern similar to the 
ARG1 locus (Figure 4.7), which belies the difference in the effect of the Pup1 and Pre3 subunits alone 
on transcription. In the case of INO1 the transcription levels correspond very accurately with 
RNApolII levels. 
 Not all inducible genes are dependent upon proteasome-mediated proteolysis. CHA1 is 
induced by multiple signals, such as stress to the cell wall integrity triggered by treatment with Congo 
red (Garcia et al. 2004) or with elevated temperatures (A. Leung, Personal Communication). 
Alternatively, excess serine levels in the media induce CHA1 expression (Petersen et al. 1988; 
Bornaes et al. 1993; Holmberg and Schjerling 1996), which is the method I selected to use to induce 
CHA1 because it provides a rapid and robust response with little secondary impact on the cell as 
compared to heat shock. Induction of CHA1 with serine was unaffected by addition of MG132 in both 
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the PUP1PRE3pdr5 and pup1pre3pdr5 strains (Figure 4.8), providing an example of a gene not 
dependent on proteasome-mediate proteolysis for activation. The recruitment of RNApolII at this 
locus is affected by the triple inhibition of loss of Pup1 and Pre3 function with the addition of MG132 
(Figure 4.9). However, the level of Rpb3 detected at CHA1 remains substantially higher than when 
no serine is added to the cell, and this residual presence of RNApolII may explain why I observe 
CHA1 transcription even when I inhibit the proteasome in pup1pre3pdr5 yeast.  
 
Discussion 
 I have examined the effects of proteasome inhibition on four model inducible genes. Using 
MG132 to inhibit the proteasome, GAL induction is significantly reduced. However, the variability 
between different laboratories and the knowledge that MG132 incompletely inhibits the proteasome 
leaves uncertainty regarding the degree to which proteasome mediated proteolysis is necessary for 
GAL gene induction. For example, in my analysis, MG132 inhibits GAL gene induction by 
approximately eighty percent. The nature of the remaining twenty percent of transcription is also of 
interest. Does this represent a proteasome independent set of transcripts or does this remaining 
transcription reflect the incompleteness of inhibition achieved by biasing the inhibition of the 
proteasome to the chymotryptic activity? I believe that the data from ARG1 and INO1 in the 
pup1pre3pdr5 support that residual GAL transcription arises from incompletely inhibiting the 
proteasome rather than reflecting transcription that is independent of proteasome mediated proteolysis 
because the more thorough inhibition of the proteasome in pup1pre3pdr5 significantly reduces the 
level of transcripts produced to near basal amounts. Inactivating Pup1, Pre3, and deleting PDR5 in a 
strain that is galactose positive will allow this hypothesis to be tested. 
 The differences in effect of loosing Pup1 and Pre3 proteolytic activity between ARG1 and 
INO1 transcription lead to an interesting problem. It makes sense that, as has been described in vitro 
(Kisselev et al. 2006), that the rate at which proteolysis for a given substrate should be differentially 
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dependent on each of the proteolytic functions. For example loss of the caspase-like activity would 
have a significant effect on proteins with many acidic residues but not on those with relatively few 
acidic amino acids. But although the rate of proteolysis may depend on the substrate’s composition, 
proteolysis should eventually occur. Furthermore the non-proteolytic processes of the proteasome —
de-ubiquitylation, unfolding, and translocation —should inhibit the function of a substrate. If there is 
a limited potential to increase the proteasome recruitment to an actively transcribed gene compared to 
a much greater potential to increase the recruitment of the critical proteasomal substrate, say an 
activator, then slowing down the rate of proteolysis would lead to occupied proteasomes that cannot 
function. Proteasomes without caspase-like or tryptic activities will be jammed with to-be-digested 
substrates differently than proteasomes with inhibited chymotryptic activity. 
 The relationship between the rate of proteolysis and substrate composition 
emphasizes the need to identify the important proteasome substrates in transcription. Inhibition of the 
proteasome leads to loss of RNApolII concentration to the very 5’ of the ORF, consistent with a 
defect in recruitment. The instability and ubiquitylation of transcription activators make these proteins 
primary candidates. The characterization of the UPS regulation of Gcn4 provides valuable tools in 
testing the contributions of activator proteolysis. In addition to inhibiting proteolysis acutely in the 
pup1pre3pdr5 strain and inhibiting ubiquitylation using Cdc4 temperature sensitive mutants, the 
phosphorylation of Gcn4 can be blocked using cis mutations to three threonines and two serines that 
are necessary for Gcn4 phosphorylation (gcn4-3T2S). Importantly, although gcn4-3T2S cannot be 
ubiquitylated by Cdc4, induction of ARG1 still occurs even with thermal inactivation of Cdc4 
temperature sensitive mutants. If the report that gcn4-3T2S can also activate ARG1 when treated with 
MG132 extends to the pup1pre3pdr5 strain then it will be useful to study the changes in the initiation 
complex that are recruited to Gc4n regulated promoters, such as ARG1. Furthermore, the ability of 
gcn4-3T2S to activate transcription in the context of proteasome inhibition is suggestive that the basic 
amino acid sensing pathway remains intact and that the defect is indeed with transcription. 
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Chapter Five: Proteasome Inhibition and Global Transcription 
Introduction 
 In this chapter I will discuss the effects on global transcription of treating yeast with the 
proteasome inhibitor MG132. In contrast to similar studies in the past (Fleming et al. 2002; Dembla-
Rajpal et al. 2004) I am doing this in the context of inactive PUP1 and PRE3, which as I have 
demonstrated increases sensitivity to proteasome both at the physiological level of proliferation 
(Chapter Three) and the level of transcriptional activation (Chapter Four).  
A surprisingly small number of genes were identified as targets of the proteasome inhibitor 
PS341 (bortezomib/Velcade) in a time-series study of transcription (Fleming et al. 2002). This study 
is noteworthy as both one of the first genome-wide characterization of the proteasome and its 
inhibitors and in its contribution for understanding the proteasome in S. cerevisiae. It was from this 
study that the drug efflux-pump PDR5 was convincingly demonstrated to inhibit the potency of 
proteasome inhibitors in vivo. Furthermore, Fleming et al identified Rpn4 as an important regulator of 
the transcriptional response to PS341. Rpn4 is an important activator that induces the expression of 
most proteasome subunits and ubiquitylation in response to decrease proteasome activity (Fleming et 
al. 2002; Dembla-Rajpal et al. 2004). Even after four hours of treatment, the majority of the genes 
with expression altered after treatment with PS341 depend on functional Rpn4. 
Another set of analysis, by the Rymond group, found substantially more genes with 
expression that was elevated in the presence of proteasome inhibitor, in this case MG132 (Dembla-
Rajpal et al. 2004). Included in their set of genes that were induced by proteasome inhibition were 
proteasome subunits, genes likely involved in responding to general cellular stressors such as 
temperature, and mitochondrial function. 
One other notable genome wide analysis of the proteasome examined the association of the 
proteasome to genes rather than the effects of proteasome inhibition on transcription (Auld et al. 
2006). The Silver laboratory performed these ChIP-on-chip (microarray analysis of DNA from a 
chromatin immunoprecipitation) experiments using epitope tagged versions of Pre1 (20S proteasome 
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-subunit), Rpt1 (19S proteasome base), and Rpn11 (19S proteasome lid) to determine the 
distribution and overlap of these subunits. Tagging proteasome subunits alters the stability of the 
proteasome (F. Geng, personal communication), and consequently to what extent a proteasome 
subunit associates with chromatin independently of the other subunits remains in doubt. However, 
this study did suggest that the majority of proteasome association with chromatin was with highly 
transcribed genes, consistent with the possible role of the proteasome as a regulator and even 
facilitator of transcription. 
I examined the data from these experiments to better understand how the proteasome 
regulates transcription. In particular I was looking for classes of genes that were both repressed by 
proteasome inhibition and bound by the proteasome subunit Pre1 (the 20S component) to reveal 
common regulatory patterns. Instead, I found that there was relatively little overlap between the two 
expression data sets or with either of the expression sets and Pre1 ChIP signals (Figure 5.1). Indeed 
the consistency among the expression data was particularly poor for repressed genes. The poor level 
of agreement among the data sets might reflect differences in the activity of the drugs used, strain 
differences, and laboratory-to-laboratory variation such as what I found with GAL1 transcriptional 
inhibition by MG132 (Chapter Four). Alternatively, the data might be due to failure to completely 
inhibit the proteasomal activity. I showed that the combined chemical and genetic approaches to 
target all three proteolytic sites of the proteasome increases my ability to detect a role of proteasome-
mediated proteolysis in transcriptional activation for certain genes (Chapter Four). With the strain 
that I developed and characterized that have increased sensitivity to proteasome inhibition, I can study 
the genome wide transcription effects of inhibiting proteasome-mediated proteolysis without concern 
that the inhibition of the proteasome may be incomplete. Furthermore, studying the genome wide 
effects of proteasome inhibition can give new insights on the importance of the Pup1 and Pre3 
proteasome subunits in the cell. 
Based on the time series data from Millenium Pharmaceuticals (Fleming et al. 2002) the peak 
of transcriptional response to MG132 was at one hour of treatment. Therefore, I selected that time of 
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treatment for my analysis. Neither of the two expression studies used commercially available arrays, 
therefore I chose to use a Nimblegen array because it provided comprehensive coverage of the S. 
cerevisiae genome with, at the time of my experiments, the largest and most recently updated arrays 
commercially available. Furthermore, the microarray facility at Vanderbilt University Medical 
Center, where this set of experiments was conducted, had previously used this platform with success 
(V. Amman, personal communication). 
 
Experimental procedures 
Yeast strains 
 I list the strains used in the course of this study in Table 5.1. The preparation of the strains 
GAC201 (PUP1PRE3pdr5) and GAC202 (pup1pre3pdr5) was described in the methods section of 
Chapter Three. 
 Yeast were grown in YPAD cultures at an initial A 600 nm of 0.5. One part of the sample was 
left untreated while the remaining sample was treated for one hour with 50 M MG132. (Samples 
treated for two and four hours with MG132 were also collected for later analysis). 
 
Table 5.1: Yeast Strains Used 
 
Strain Genotype Source 
GAC201 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 pre3::HIS3 
pup1::leu2::HIS3 [pRS317-PUP1] [YCplac22-PRE3] gal- 
This Study 
GAC201 Mat his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 pre3::HIS3 
pup1::leu2:HIS3 [pRS317-pup1-T30A] [YCplac22-pre3-T20A] 
gal-  0 
This Study 
 
RNA extraction and purification 
 I collected RNA from 15 ml of yeast using a Hot Phenol RNA extraction method. Cells were 
lysed in RNA extraction buffer (50 mM sodium acetate (pH 4.8), 0.5% SDS, and 10 mM EDTA) and 
an equal volume of acid (pH 4.3) phenol (Sigma) by incubating at 65 °C for one hour. Samples were 
chilled on ice for five minutes, centrifuged for five minutes, and the aqueous phases was collected for 
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purification through another extraction with acidic (pH 4.3) phoenol followed with a 
phenol:chloroform:isoamyl alcohol extraction. Samples were precipitated in ethanol for 20 minutes at 
–20°C. RNA was resuspend in nuclease free water. Contaminating DNA was removed with DNaseI 
(Roche). RNA was further purified by passing the RNA solution through RNeasy coloumns (Qiagen) 
and delivered to the Vanderbilt University Medical Center Functional Genomics Shared Resource 
Center  (FGSRC) for labeling and hybridizaiton. 
 
Labeling and Hybridization 
 All RNA Preps submitted to the FGSRC were run on an Agilent 2100 Bioanalyzer to assess 
RNA integrity. Those samples meeting minimum requirements of RNA integrity number of 7.0 and 
greater were used to generate cDNA targets for hybridization to Nimblegen arrays. 10ug of total RNA 
from each sample was reverse transcribed at 42 °C using 400 units Superscript II (Invitrogen) in the 
presence of 6 g anchored oligo dT and an Amino-allyl tagged dUTP (Sigma).  Final concentrations 
of dNTP's in the reaction were 200 M dA,dG,dC, 51 M dT, and 149 M AAdUTP (Sigma).  cDNA 
targets generated were incubated with NaOH to hydrolyze any remaining total RNA, then neutralized 
with HCl, and cleaned over Qiaquick PCR Purification columns (Qiagen) following manufacturer’s 
protocol with the exception of the following:  Two washes were completed with 80% ETOH instead 
of PE buffer and the elution was completed with nuclease-free H2O instead of EB buffer.  The targets 
were dried to completion and then coupled to either ester-linked Cy3 dyes (GE) in 0.1 M Sodium 
Bicarbonate, pH. 9.0 for 120 minutes in a 20 l volume. After quenching of unbound dye with 4 M 
Hydroxylamine (Aldrich) Cy3 targets were cleaned up over Qiaquick columns (Qiagen).  The targets 
were quantitated and then a total of 125 ng of each target was dried to completion.  Each target was 
resuspended in one of Nimblegen’s Sample Tracking Controls, mixed with Hyb cocktail, heat 
denatured and then loaded on the 12-plex arrays, following standard Nimblegen protocols.  The 
targets were hybridized 16 hours at 42 °C on a Maui Hyb Station (BioMicro Systems, Inc., 4 chamber 
model) mixing program B per Nimblegen protocol.  Following post hybridization washes, as per 
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standard Nimblegen protocol, all arrays were scanned on an AXON 4000B scanner and gene 
expression levels were determined using the associated feature extraction software (V. Amman, 
personal communication). 
 
Data Analysis 
 Support for the data analysis of the microarrays for feature extraction and the determination 
of significant difference between PUP1PRE3pdr5 and pup1pre3pdr5 using log-odds ratios was 
provided by D. Vaka and J. Huang. Significance for comparisons between untreated and MG132 
treated samples was based on p-values < 0.05 from student’s t-test and FDR values < 0.05 when 
indicated. Cluster analysis using a Self Organizing Map algorithm and heatmap generation was done 
using MeV_4_5 software (Saeed et al. 2003). Identification of promoter motifs was done using 
CERES software (Morris et al. 2010). Data from the Fleming et al microarray experiments was 
retrieved using yMGV (Lelandais et al. 2004). Data from Dembla-Rajpal et al and Auld et al 
experiments was obtained in the supplemental data (Dembla-Rajpal et al. 2004; Auld et al. 2006). 
 
Results 
Meta-analysis of previous genome wide studies of the proteasome 
 I examined the published data sets from three genome-wide analysis of the proteasome in S. 
cerevisiae. Millenium Pharmaceuticals characterized the small molecule proteasome inhibitor that 
they developed, PS341 (bortezomib/Velcade), in a times series set of experiments (Fleming et al. 
2002). I compared the genes described as significant after one hour of treatment to those genes 
discovered by the Rymond group (Dembla-Rajpal et al. 2004), which looked at MG132 on using a 
macroarray of dot blots using P33 labeled nucleotide probes. The degree of overlap between these two 
data sets was rather poor (Figure 5.1). For example, of the 1026 genes Dembla-Rajpa et al 
determined to be significantly induced upon MG132 only 65 (6%) were common to the genes 
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identified by Fleming et al as significantly induced with PS341. In comparison 13 of the 1026 genes 
al in the Dembla-Rajpa et al up-regulated set were also in the repressed genes reported by Fleming et. 
 I also compared the effects of proteasome inhibition on gene expression to genome 
localization of the 20S proteasome subunit Pre1 by the Silver laboratory (Auld et al. 2006). I did not 
expect to find a significant number of genes that were induced with proteasome inhibitor to have high 
concentrations of proteasome associated at the locus. Consistent with that expectation, none of the 
genes reported to be induced by Fleming et al were reported to have strong Pre1 ChIP signals 
associated with their locus, and only 1% of the over expressed genes in the Dembla-Rajpal data set 
were represented in the anti-Pre1 ChIP enriched genes. There were only marginally more repressed 
genes in common with the Pre1 binding, which was not strong support for direct regulation of those 
genes by the proteasome. 
 The disparity between these data and my findings that the use of chemical inhibition of the 
proteasome can be improved by combining small molecule inhibitors with genetic inactivation of 
non-targeted proteolytic subunits was sufficient motivation to study the genome wide transcriptional 
effects of proteasome inhibition in strains without active Pup1 and Pre3. 
 
Transcriptional consequences of inactive pup1 and pre3 
 Before examining the effects of acute treatment with proteasome inhibitor in yeast without 
active Pup1 and Pre3, I wanted to determine what the transcriptional consequence of these 
inactivating mutations on their own had. Therefore, I compared gene expression of untreated 
PUP1PRE3pdr5 to untreated pup1pre3pdr5 yeast. This analysis revealed relatively few genes that 
were significantly affected (Figure 5.2). Many of the genes with altered expression in pup1pre3pdr5 
yeast were mitochondrial encoded. The level of transcripts detected was towards the lower limits of 
signal consistent with a loss of mitochondrial transcription and perhaps genome. Furthermore, many 
of the other genes that were detected as having significantly lower expression in the pup1pre3pdr5 
strain than the PUP1PRE3pdr5 strain were nuclear genes encoding for mitochondrial functioning 
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proteins such as ATP-synthase or components of the electron transport chain (ETC) (Table 5.2). 
Other genes with decreased expression in pup1pre3pdr5 yeast include several hexose transport 
proteins. Thus, the overall picture that arises from this analysis is that pup1pre3pdr5 are respiratory 
deficient. Of the few genes are expressed at significantly higher levels in pup1pre3pdr5 yeast (Table 
5.3), PRE3 is notable, representing a proteasomal subunit, which, because the loss of proteasome 
function induces the expression of proteasome subunits, may reflect that a degree Rpn4 accumulation 
and activation. Beyond the changes in these few genes, untreated pup1pre3pdr5 is nearly 
indistinguishable, transcriptionally, from PUP1PRE3pdr5.  
 
Table 5.2: Genes with significantly lower gene expression in pup1pre3pdr5 compared to 
PUP1PRE3pdr5. (ETC: Electron Transport Chain; mtRNA: mitochondria RNA). 
 
GENE Fold Change p Function Complex 
Q0130 OLI1 689.00310 0.00000   ATP synthase 
Q0105 COB 89.85021 0.00133   ETC 
Q0050 AI1 84.95832 0.00175 mtRNA processing   
Q0110 BI2 40.11398 0.00000 mtRNA processing   
Q0065 AI4 38.60458 0.00037 mtRNAprocessing   
Q0045 COX1 29.09804 0.00011   ETC 
Q0075 AI5_Beta 27.69429 0.00069     
Q0070 AI5_Alpha 18.60562 0.00105 mtRNA processing   
Q0160 SCE1 15.66131 0.00053 mtRNA processing   
Q0055 AI2 14.56365 0.00157 mtRNA processing   
YDL181W INH1 13.60847 0.00087   ATP synthase 
Q0080 ATP8 10.49211 0.00357   ATP synthase 
Q0085 ATP6 8.12190 0.00039   ATP synthase 
YHR092C HXT4 7.98329 0.00022 Hexose transport   
Q0275 COX3 7.13139 0.00008   ETC 
YKL163W PIR3 5.51305 0.00070 Cell Wall Stability   
YDR342C HXT7 4.57266 0.00013 Hexose transport   
YDR343C HXT6 4.45961 0.00003 Hexose transport   
YOR065W CYT1 4.45574 0.00048   ETC 
YHR001W-A QCR10 3.69016 0.00127   ETC 
YOL058W ARG1 3.60404 0.00099 Amino acid biosynthesis   
YFL014W HSP12 3.04083 0.00113 Cell Stress   
YGR183C QCR9 2.60904 0.00013   ETC 
YEL024W RIP1 2.38070 0.00036   ETC 
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Table 5.3: Genes with significantly higher gene expression in pup1pre3pdr5 compared to 
PUP1PRE3pdr5. 
 
GENE 
Fold 
Change p Function Complex 
YKL071W YKL071W 11.33949 0.00016     
YJL001W PRE3 3.46515 0.00218   Proteasome 
YBR085W AAC3 3.36576 0.00071 Mitochondrial ATP transport   
YNR034W SOL1 2.59116 0.00114     
YEL071W DLD3 2.52412 0.00031     
 
 
Expression Differences Upon Treatment with MG132 
 To test the effects of proteasome inhibitor on transcription, I looked at the effects of MG132 
in the PUP1PRE3pdr5 yeast. Using an FDR threshold of 0.05, no genes were significantly reported 
as being changed. With a less stringent threshold of significance (p value < 0.05), only 72 genes of 
the 5777 assayed were reported as significantly changed. Even with this generous threshold, the fold 
change for these genes is relatively modest, as apparent by the similarity of the heatmap of the 
statistically significant changes in expression (Figure 5.3). The leftmost three columns represent the 
Log2 expression of untreated PUP1PRE3pdr5 yeast. The expression of these three roughly matches 
those of the right set of three values of expression after one hour of MG132 treatment. These data 
reflect the general resistance of this PUP1PRE3pdr5 strain to MG132, which may be due in part to 
the expression of the proteasome subunits on a plasmid. Because of the lack of substantial changes in 
the expression profile, I did not invest significant time further investigating the data I obtained for 
PUP1PRE3pdr5. Instead I turned my attention to focus on the transcription changes of pup1pre3pdr5 
yeast in response to MG132 treatment. 
 The combination of chemical inhibition with MG132 and genetic inactivation of the catalytic 
sites of Pup1 and Pre3 results in an increase in the number of genes that change in response to 
proteasome inhibition as compared to PUP1PRE3pdr5 (Figure 5.5). Using the same threshold for 
significance, 671 genes change in response to MG132, which is nearly ten times the number detected 
in PUP1PRE3pdr5. Between pup1pre3pdr5 and PUP1PRE3pdr5 there is limited overlap in genes 
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with significant changes in expression, which may reflect a bona fide difference in genes regulated by 
the proteasome or represent a high false positive rate tolerated to detect any significant level of 
change in PUP1PRE3pdr5 yeast. Importantly, there are no cases in which a gene was induced in 
pup1pre3pdr5 and repressed PUP1PRE3pdr5, or vice versa. Using a more stringent cutoff of an FDR 
threshold less than 0.05, 59 genes still are determined to be significantly altered in expression in 
response to MG132 treatment (Figure 5.4).  
In contrast to PUPPRE3pdr5, in which the heatmap of untreated samples was nearly identical 
with samples treated with MG132 (Figure 5.3), the left-side (untreated) of the pup1pre3pdr5 heatmap 
does not look like the right-side (treated). In fact, there are rather striking examples of strongly 
induced and strongly repressed genes (Figure 5.4). However, unlike comparing the difference 
between untreated pup1pre3pdr5 and untreated PUP1PRE3pdr5, no clear pathways are obvious in 
this set.  
To be able to make sense of the large number of genes changing in pup1pre3pdr5 I search for 
transcription factor binding motifs that were either enriched in genes that were induced by MG132 
treatment or genes that were repressed by MG132. I used this approach for several reasons. First, 
common transcription factor motifs in the promoter represent a potential set of genes with a common 
regulator, which would be useful as comparison to Gcn4 regulation of ARG1 and Ino2/Ino4 regulation 
of INO1 in order to better define what steps in transcriptional activation are changed in a proteasome-
dependent manner. Second, genes that share common transcription factor motifs often belong in the 
same cellular pathway, which provides a biological meaning to the changes in gene expression that 
are occurring. Finally, this approach was simplified by the availability of a searchable database of 
yeast promoters with their corresponding binding motifs, based on both sequence prediction and 
empirical evidence from ChIP experiments (Morris et al. 2010). 
The log2 fold change in the significant genes that I found in this experiment took on a nearly 
normal distribution (Figure 5.6 A): very few genes had substantial changes in excess of four-fold 
more (yellow) or less (blue) than untreated yeast, whereas the majority of genes found to be 
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significantly different had one and half to two fold changes. Moreover, with slightly more than half 
the significant genes induced in response to MG132, it becomes straightforward to test if transcription 
factor motifs predicted by the CERES algorithm to be enriched in induced genes actually are 
enriched. If a transcription factor motif is incorrectly predicted by the CERES algorithm to be 
enriched for induced genes, then plotting log fold changes of the genes that have a given motif reveals 
whether such genes are randomly assorted with up (yellow) or down (blue) regulated genes or if there 
is indeed a particular bias for up-regulation (yellow). Rpn4 (Figure 5.6 B) an activator that is known 
to induce transcription of proteasome encoding genes in response to proteasome inhibition provides 
an example for this type of analysis. CERES identified this as a motif commonly occurring in genes 
induced by MG132, as is demonstrated by plotting the log fold change for genes with Rpn4 motifs. 
Similarly, Fhl1, which regulates many ribosomal subunits, which Fleming et al observed to be 
repressed in response to proteasome inhibition is detected in my analysis as significantly enriched in 
the repressed gene category (Figure 5.6 C). 
Other transcription factors with enrichment in induced genes are Hsf1 (Figure 5.7 A), Msn2 
(Figure 5.7 B), Msn4 (Figure 5.8 C). These are genes commonly associated with response to cell 
stress such as heat-shock, osmotic stress, or accumulation of unfolded proteins as would occur with 
severe inhibition of the proteasome. Not observed in previous genome-wide studies, there is 
significant enrichment of Gcn4 (Figure 5.8 A), Rap1 (Figure 5.8 B), and Sfp1 (Figure 5.8 C). These 
represent amino-acid biosynthesis genes (Gcn4) and ribosomal genes (Sfp1) that indicate that 
concomitant with an increase in chaperones and proteins in the UPS to handle the accumulation of 
unfolded and damaged proteins there is a decrease in translation to prevent further accumulation of 
protein levels. 
Compared to previous analysis of transcription response to proteasome inhibition, my 
analysis tended to pick out different genes (Figure 5.9). Part of this is expected because the 
physiological effects of proteasome inhibition are different in the pup1pre3pdr5 than typical wild 
type strains. However, the degree of overlap with the other two data sets surprisingly low, particularly 
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with Dembla-Rajpal with not only lower agreement as a percentage of the genes they identified but 
also in terms of disagreement as to the direction in which genes responded to proteasome inhibitor.  
I also compared the genes that I found significant to the genes that Auld et al identified as 
being bound by Pre1 (Figure 5.10) because having found more genes that were repressed by 
proteasome inhibition, I speculated that I would find more genes that were differentially regulated in 
response to MG132 that were bound by Pre1. To a modest extent this is true (25 repressed genes with 
significant Pre1 binding compared to 15 genes in the Debmla-Rajpal and Fleming datasets 
combined). However, the majority of Pre1 bound sites did not significantly change. 
 
Discussion 
One of the most striking features of studying global gene expression changes in response to 
proteasome inhibition is the relatively small number of genes that are affected. The number of genes 
that I identified as significantly changed represents little more than ten percent of the entire genome. 
Considering the importance of the proteasome to the cell, as evidenced by the growth defects of 
pup1pre3pdr5 yeast treated with MG132, there is a robustness in transcription to proteasome 
inhibition that is not just the result of incompletely targeting the three proteolytic sites. I believe that 
this robustness occurs for two reasons. First, the patterns of gene expression observed with treatment 
of the cells with proteasome inhibitor – increase in proteasome subunits and chaperones and 
corresponding transcriptional decrease in protein synthesis – provide a buffer on the impact of loss of 
proteasome function. Second, much of the evidence that leads to the hypothesis of a direct role of the 
proteasome in transcription is based on studies of inducible genes. My study, and the previous gene 
expression profiles, used rich media that did not induce many genes. Consequently the genes that tend 
to provide evidence for a role of the proteasome in transcription are off or at basal levels throughout 
these experiments. One notable exception is Gcn4 and its transcriptional targets. ARG1 expression 
was modestly (1.4 fold) decreased by proteasome inhibition. This is unexpected when its expression 
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should be towards basal levels. Nevertheless, observing many Gcn4 targets as repressed by 
proteasome inhibition is encouraging for use of this activator in studying the connection between 
proteolysis and transcriptional activation. In contrast to Gcn4, Msn2 dependent transcripts are 
induced in the context of proteasome inhibition. This is interesting because Gcn4 and Msn2 are 
regulated by similar pathways such as Srb10 (Chi et al. 2001). Thus, the separation of response 
between Gcn4 and Msn2 is interesting and studying the two in parallel could prove insightful for how 
the UPS stimulates activators such as Gcn4 but inhibits Msn2. 
Related to the small number of genes that were observed to be regulated by the proteasome, 
there is relatively little overlap between Pre1 binding and MG132 regulated gene expression. This is 
an important concern, because if the proteasome-mediated proteolysis is directly involved in 
regulating transcription it should not only be detected with actively transcribed genes but also be 
associated with those genes that significantly change in response to MG132. The differences in genes 
observed in studying Pre1 binding and proteasome inhibition may be due to strain differences, 
consequences of using tagged proteasome subunits for ChIP, or once again the inability to look at 
inducible genes in rich YPAD media.  
One of the unanticipated findings is the loss of mitochondrial gene expression in 
pup1pre3pdr5 even without treatment with MG132. It will be interesting to determine if this reflects a 
loss of transcription or a more severe loss of mitochondrial DNA. Generating another pup1pre3pdr5 
strain will be important to test if the mitochondrial defect is a consequence of prolonged loss of Pup1 
and Pre3 function or if it represents a unique event in the history of this particularly strain. On-the-
other hand, the pup1pre3pdr5 strain had a very similar transcription profile to PUP1PRE3pdr5 yeast, 
suggesting that other significant changes are not already occurring that would complicate studying 
transcription in pup1pre3pdr5. 
The one significant result from this work is that it highlights the contribution of removing 
Pup1 and Pre3 to improving the ability to detect transcriptional defects as a consequence of acute 
proteasome inhibition with MG132. There was significantly more numerous and larger changes in 
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response to MG132 in the pup1pre3pdr5 strain than with the PUP1PRE3pdr5 yeast, validating it as 
an important tool to study transcription and proteasome-mediated proteolysis. 
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Chapter Six: Protein Turnover and Transcriptional Activation 
My research focused on addressing if the proteasome regulates transcriptional activators 
through licensing in which activators are ubiquitylated and destroyed as part of transcription. From 
this model of activator function, two testable models arise. 1) Activators should not stably associate 
with their target promoters when transcription occurs. 2) Inhibition of proteolysis should inhibit the 
ability to activate transcription. To test the first prediction, that activators do not lock onto promoters 
during transcription, I used the classical activator Gal4 to demonstrate that this activator is labile and 
undergoes turnover on the promoter during conditions of active transcription (Chapter Two). I have 
also used Gal4 to demonstrate sensitivity of transcriptional activation to proteasome inhibition 
(Chapter Four). Developing a new strain of yeast that has increased sensitivity to proteasome 
inhibition (Chapter Three), I also demonstrated that two other inducible genes, ARG1 and INO1, 
failed to activate when treated with MG132 (Chapter Four). However, not all genes are regulated by 
the proteasome in this fashion. Activation of CHA1 is not affected by shutdown of the proteasomal 
proteases (Chapter Four). I also extended my work with the new yeast strain, which improves 
inhibition by combining chemical inhibition of MG132 with the genetic abolition of the critical 
catalytic sites of Pup1 and Pre3, to characterizing the whole genome transcriptional defects of loosing 
proteasome function. The improved method of proteolytic inhibition enables the detection of many 
more genes under the control of the proteasome than is possible by simple treatment of MG132 
without inactivating Pup1 and Pre3 (Chapter Five). 
Activator turnover may occur by non-proteasome-mediated means through other chaperones 
or by basic association-dissociation kinetics. Furthermore, proteasome inhibition may not regulate 
transcription through transcription activator but by stabilizing repressors or impairing the signaling 
pathways for induction. However, given the known role of ubiquitylation and ubiquitin ligases in 
regulating several model activators such as Gal4 and Gcn4 and the importance of proteasome-
mediated proteolysis for hundreds of genes in the yeast cell, the potential for the proteasome to 
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regulate transcription at the level of the activator is not only a plausible model, but one that seems to 
best account for the known data. 
Many improved techniques and basic characterization of the impact of the proteasome on 
transcription should provide for the ability to advance the understanding of the mechanisms of how 
the proteasome regulates transcriptional activation. The corrected system for studying transcription 
activator turnover, the improved inhibition of the proteasome, and a list of genes that are regulated by 
the proteasome are tools that my work provides that can be combined with existing and new 
mutations in model activators (e.g. Gal4 and Gcn4) and the promoters of the genes that they target 
(e.g. GAL1 and ARG1) and emerging data regarding the positioning of proteasomes across the 
genome and in response to changes in transcription to advance this field. 
The immediate steps that I would take would be to use the activator Gcn4 and its mutant 
variant gcn4-3T2S, which by virtue of its inability to be phosphorylated also bypasses the requirement 
for ubiquitylation and functional proteolysis to drive transcription (Lipford and Deshaies 2003). The 
changes in the recruitment of the initiation complex should be investigated in detail as presumably 
proteasome inhibition decreases the levels of RNApolII that can be recruited to Gcn4 regulated 
promoters. The gcn4-3T2S mutant may also be a tool to determine if ubiquitylation and proteolysis 
regulate activator turnover. 
I have shown that the typical approach of treating yeast with MG132, even with an impaired 
drug efflux system from deleting PDR5, does not achieve a very strong phenotype. Cell proliferation 
in this context continues to occur, and it has been documented that several known ubiquitylated 
proteins, such as cyclins, are notably absent from proteomic profiling of ubiquitylated proteins even 
when MG132 or other proteasome inhibitors are used to stabilize ubiquitylated substrates. I have 
demonstrated that a much more robust inhibition of the proteasome can be accomplished by not only 
targeting the chymotryptic proteasome subunit with MG132 but by also removing the catalytic 
centers of the tryptic and caspase-like subunits. This approach results in significant impairment of the 
cell proliferation and increased accumulation of ubiquitylated substrates. The combined chemical and 
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genetic inhibition of the proteasome should thus provide a valuable technique for other researchers 
studying the biology and mechanisms of the UPS. 
My work also suggests that more research needs to be directed to the contributions of the 
tryptic and caspase-like subunits of the proteasome to various cell processes. I am working on a next 
generation version of yeast that not only is amenable to studying galactose induction but also is able 
to separate the relative contributions of Pup1 and Pre3. This work may revise our current model of the 
chymotryptic subunit being the rate limiting subunit for all processes regulated by the proteasome. 
Such information would not only alter our understanding regarding the function of the proteasome but 
might also redesign approaches to inhibiting the proteasome in human disease. 
My work has examined two predictions of the proteasome to regulate transcription. The 
natural consequence of destroying activators during transcription is that there should be rapid 
turnover of the activator. The results of Nalley et al for Gal4 using competitive ChIP to measure this 
turnover provided compelling evidence that a potent and unstable activator none-the-less locked onto 
the promoter during transcription (Nalley et al. 2006). However, when using this technique I noticed 
that 17--estradiol in the absence of competitor Gal4 increased the level of endogenous Gal4 detected 
with ChIP. This fact alone explained the apparent stability of Gal4. An alternative means of inducing 
competition using 4-hydroxy tamoxifen did not induce the same artifact. Using this method 
demonstrated that Gal4 does not lock onto the promoter during active transcription but remains 
dynamic.  
My work studying the effects of proteasome inhibitors accomplished two things. First, my 
work led to the development of a new strain that has increased sensitivity to proteasome inhibition. 
Not only did this technical improvement lead to an improved means to study the proteasome in 
transcription but it also provides a useful resource to study other pathways regulated by the UPS. 
Moreover, this strain demonstrates the importance of Pup1 and Pre3 to the biology of S. cerevisiae. 
Inactivation of these two proteasome subunits results in decreased proliferation, accumulation of 
ubiquitylated protein, and even impacts the activation of certain genes. These subunits have typically 
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been considered secondary to the chymotryptic activity of Pre2, but my data suggest that further 
investigation needs to be directed towards the tryptic and caspase-activities alongside the 
chymotryptic subunit. 
Finally I have shown that, while not a universal mechanism for regulating transcription, 
inhibition of the proteasome can inhibit the induction of certain genes. These data reshape our 
understanding of the proteasome in transcription. Previous means of inhibiting the proteasome by 
chemical means using MG132 alone have had difficulty revealing the role of proteolysis in 
transcription. However, inhibiting multiple subunits by combining chemical and genetic approaches 
demonstrates an important role of proteolysis in regulating transcriptional activation. Given the 
current evidence, an important regulatory role of the proteasome through proteolysis is plausible. 
What then would be the role of proteasome-mediated proteolysis in transcription? As central 
regulators of gene expression, transcription activators are likely targets of proteolysis. Targeting 
activators would generate a cycle of activator recruitment, transcription, and activator destruction 
followed by renewed activator recruitment and so on. Thus, when this cycle of activation is arrested 
(at renewed activator recruitment), transcription rapidly stops. I propose that a key function of 
proteasome-mediated proteolysis is to maintain such transcriptional programs in a responsive state to 
fluctuations in the signaling environment. 
Proteasome-mediated proteolysis may also provide dynamic control to the process of moving 
from an assembled initiation complex to effective transcription elongation. The assembled initiation 
complex —including not just RNApolII and its general transcription factors, but also the mediator 
complex, several co-activators, and critically the activator itself —must be re-arranged to permit 
efficient transition to the elongation phase of transcription. There has been speculation that in the 
process of transcriptional activation there is a special pioneer round of transcription (Jiang and Gralla 
1993; Yudkovsky et al. 2000; Ansari and Hampsey 2005; Arndt and Winston 2005; Malik et al. 
2007; Singh and Hampsey 2007; Tran and Gralla 2008; Kaderi et al. 2009). In this round of 
transcription, the transition from initiation to elongation phases occurs without fully recruiting 
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components of the elongation or the co-transcriptional RNA processing machinery. Instead this initial 
round of transcription remodels the chromatin along the gene to facilitate greater efficiency in 
subsequent rounds of transcription, an effect that has been termed “transcriptional memory” (Ng et al. 
2003; Xiao et al. 2005; Kaderi et al. 2009). I propose that instead of there simply being a pioneer 
round and then suddenly efficient transcription, there is instead a gradual transition from inefficient 
transcription to effective transcription that is accelerated by the ubiquitylation and subsequent 
proteolysis of activators. 
In my model of how proteolysis activators transcription (see Figure 6.1) there is a clear 
progression wherein the activator is first phosphorylated (Figure 6.1-B), then ubiquitylated (Figure 
6.1-C), and ultimately destroyed (Figure 6.1-D). Initial, or pioneer, rounds of transcription are 
inefficient, with slow rates of transcription and failure to recruit elongation factors and co-
transcriptional RNA processing enzymes (Figure 6.1-A). Phosphorylation of the activator alters the 
association of the transcriptional initiation complex so that RNApolII can transition more quickly 
from being recruited to the promoter into the elongation phase of RNA synthesis. However, the 
phosphorylation of potent activators, such as Gal4 and Gcn4, might be too effective, causing 
premature escape of RNApolII before the phosphorylation of RNApolII at its CTD and before the 
recruitment of elongation and co-transcriptional processing complexes (Figure 6.1-B). 
Ubiquitylation, therefore, functions analogously to a resistor in an electrical circuit in that it stabilizes 
the progression of RNApolII from an initiated to elongating state (Figure 6.1-C). How precisely this 
is achieved is not yet clear. One possibility is that ubiquitylation serves as a scaffold to stabilize the 
initiation complex by increasing the interaction surface. Alternatively, instead of being recognized by 
the initiation complex, ubiquitin because of its bulk in an already massive initiation complex could 
act as a wedge to misalign the initiation complex into an arrangement that delays the escape of 
RNApolII from the promoter. In addition to its role as a “resistor,” ubiquitylation of the activator also 
serves to recruit the elongation factors (Hobeika et al. 2007) and the proteasome, which is required 
for efficient histone methylation (Ezhkova and Tansey 2004; Laribee et al. 2007) and transcriptional 
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elongation (Ferdous et al. 2001; Lassot et al. 2007). So far the evidence points to non-proteolytic 
roles for the proteasome in the processes of histone methylation and RNApolII elongation. The 
proteolytic role of the proteasome, therefore, is to modulate the resistance of activator ubiquitylation 
(Figure 6.1-D) and to bail out stalled RNApolII (Svejstrup 2003; Somesh et al. 2005). An activator 
with multiple conjugated ubiquitin proteins conjugated not only is a more powerful “resistor” but now 
becomes a target for proteolysis resulting in the dual benefit reducing the resistance and increasing 
the dynamics of the activator to be more responsive to changes in inducing signals. 
In my model, ubiquitylation and proteolysis is one means to transition to efficient 
transcription. Cycles of ubiquitylation and proteolysis speed the change from inefficient and 
ineffective pioneer rounds of transcription to a state of “transcription memory” —be it delocalization 
of the chromatin to the nuclear periphery (Brickner and Walter 2004; Brickner 2009; Brickner 2010), 
the formation of chromatin loops (Ansari and Hampsey 2005), opening the chromatin by nucleosome 
remodeling (Kundu et al. 2007), or nucleosome modifications such as methylation of histone H3 on 
lysine 36 (Xiao et al. 2007; Youdell et al. 2008). Once this transition to a “transcriptional memory” 
state has been achieved, RNApolII is more effectively phosphorylated, elongation factors and co-
transcriptional RNA processing complexes are more effectively recruited, and the cycles of 
ubiquitylation and proteolysis of the activator are no longer necessary to increase efficient 
transcription (Li et al. 2010). Instead ubiquitylation and subsequent proteolysis of the activators 
maintains the sensitivity of the promoter complex to changes in the activating signals (Figure 6.1-E). 
There are several predictions that naturally arise from this model. First, this need not be a 
universal model for the function of transcriptional activators at all genes. Genes that are transcribed at 
low levels will not exhibit the same hallmarks of activator ubiquitylation and proteolysis that will 
occur at genes with high levels of induced transcription. Similarly, weak activators may be 
phosphorylated without pushing the rate of polymerase escape beyond the rate of phosphorylation of 
RNApolII and recruitment of elongation factors and co-transcriptional RNA processing complexes. 
Furthermore, activators do not have to be the sole target of ubiquitylation. The same pattern of 
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phosphorylation, ubiquitylation, and degradation of the human estrogen receptor co-activator SRC-3 
has been documented (Wu et al. 2007). Finally, prolonged activation should not be dependent on 
ubiquitylation and proteolysis, but only the initial build up to efficient transcription will be dependent 
on ubiquitylation and proteolysis. 
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Appendix: Publications Produced in the Course of This Thesis 
 
Collins, G.A. and Tansey W.P. The proteasome: a utility tool for transcription? Current Opinions in 
Genetics and Development (2006) 16:197-202 
A review I wrote with Dr. Tansey summarizing the recent advances in connecting the proteasome to 
transcription. In this review we discussed the potential of both the proteolytic and non-proteolytic 
roles of the proteasome throughout transcription. 
 
 
Leung, A. Geng, F. Daulny, A. Collins, G. Guzzardo, P. Tansey, W.P. Transcriptional control and the 
ubiquitin-proteasome system. Ernst Schering Foundation Symposium Proceedings (2008) 75-97. 
A review, that Dr. Tansey and the yeast group of the Tansey laboratory wrote on how the UPS 
regulates multiple steps of the transcription process. 
 
 
Collins, G.A. Lipford, J.R., Deshaies, R.J. Tansey, W.P. Gal4 turnover and transcription activation. 
Nature (2009) 461:E7 
A brief communications arising to Nature, which on the basis of my work (see Chapter 2), 
demonstrates that an artifact exists in the competitive ChIP signals for Gal4 when 17--estradiol is 
used to trigger competition. This artifact leads to the mistaken conclusion that Gal4 “locks” onto 
promoters during activation. I demonstrated that 4-hydroxytamoxifen is a more suitable trigger for 
studying Gal4 competition because it does not lead to the same artificial increase in Gal4 binding as 
was observed with 17-estradiol. Making this adjustment to the competition ChIP results in finding 
that Gal4 is labile and does not lock in on the promoter, which is a result that is in better agreement 
with previous literature describing the behavior of Gal4 and other activators. 
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Collins, G.A., Gomez, T.A., Deshaies, R.J. Tansey, W.P. Combined chemical and genetic approach to 
inhibit proteolysis by the proteasome. Yeast Submitted 
A paper describing the need for a more sensitive strain of yeast to proteasome inhibitors such as 
MG132 and demonstrating that the combination of chemically targeting the chymotryptic subunit 
with genetic inactivation of the tryptic and caspase-like subunits of the proteasome results in such a 
strain (see Chapter Three). This strain is characterized for defects in proliferation, cell cycle 
progression, stability of ubiquitylated proteins (Chapter Three), and activation of transcription 
(Chapter Four). 
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